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ABSTRACT
Many new drugs developed face oral delivery challenges and absorption due to poor
biopharmaceutical properties. Formation of solid dispersions is a very widely applied
technique for solubility enhancement of water insoluble drugs. In order to form stable
solid dispersions it is important to select appropriate excipients that will maintain the
drug in its amorphous form for an extended period of time. Selection of appropriate
excipients is critical during the development of stable amorphous solid dispersions. The
solubility parameter concept has been explored for theoretically identifying the
excipients that will be suitable based on the structure of the active. In this work, the use
of solubility parameter has been explored for strategic selection of excipients for a
model drug ibuprofen. The predicted miscibility limits are verified with experimentally
determined solubility limits. Dissolution experiments have been conducted to
demonstrate the advantage of amorphous solid dispersions.
This has been further extended by in depth thermal and chemical characterization of the
ibuprofen and Eudragit® E PO system. A phase diagram is predicted based on the
understanding of the relationship between temperature, ratio of ibuprofen and the Gibbs
free energy. Room temperature miscibility of the two components is demonstrated using
microscopic studies. The potential of ionic interactions is investigated using
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spectroscopic techniques. Melt extruded formulations are evaluated for the physical
state of ibuprofen and stability of the amorphous form.
A complete Quality by Design study was performed for preparation of ibuprofenEudragit® E PO extrudates. Risk assessment was performed using the fishbone
diagram and Failure Mode Effect Analysis and the factors influencing this melt extrusion
process were shortlisted and prioritized. The most critical factors were then assessed in
a 30 run experimental design. Torque, Glass Transition temperature, Assay and
Dissolution at 30 min were measured as responses and the results were statistically
analyzed to predict a design space. Finally, mechanistic evaluation of Ketoconazole and
Kollidon® VA 64 solid dispersions was performed using thermal techniques, dissolution,
swelling and erosion studied.
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CHAPTER 1
INTRODUCTION
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Increasing number of New Drug Entities (NDEs) filed have limited or no water solubility
thus requiring specialized formulation techniques to increase the apparent solubility of
the drug. It has been reported by several sources that about 40-50% NCEs fail due to
their low water solubility or poor ‘drug like’ properties (1-6). Amidon et al proposed the
Biopharmaceutical Classification System (BCS) which classifies drugs in four classes
based on their aqueous solubility and permeability(7) (Table 1.1). Bergström et al have
shown that drugs belonging to Class II can be completely absorbed upon oral
administration(8). By using specific solubility enhancing formulation development
techniques it is possible to increase the solubility and thus oral absorption of drugs
belonging to BCS Class II.
Table 1.1: Biopharmaceutical Classification System with examples
Class

Solubility Permeability Examples

I

High

High

Caffeine, Metoprolol, Quinidine

II

Low

High

Ibuprofen, Ketoconazole, Carbamazepine

III

High

Low

Atenolol, Metformin, Tetracycline

IV

Low

Low

Ritonavir, Acetazolamide, Oxcarbazepine

Solid Dispersion Formulation
Several approaches are available for improving the in vivo performance of poorly water
soluble

drugs

such

as

amorphous

solid

dispersions(9),

micronization(10),

complexation(11), salt formation(12), and prodrugs(13). Preparation of amorphous solid
2

dispersions is gaining high interest as it can be easily adapted to almost any drug
molecule and has a wide range of techniques available for manufacturing. The most
common techniques for preparation of solid dispersions are hot melt extrusion(14),
spray drying(15), co-grinding(16), co-precipitates(17) and freeze drying(18). Regardless
of the method of manufacturing solid dispersions increase the apparent solubility of a
drug by stabilizing its most high energy amorphous state. The polymer chains cause
physical barrier and prevent (or delay) the crystallization and agglomeration of the drug
molecules. A recent review of solid dispersions with 40 Active Pharmaceutical
Ingredients(API) shows that 82% of the compounds exhibited increased bioavailability
than the reference compound(19).
Solid dispersions are mixtures of two or more ingredients that have the drug dispersed
as amorphous ,crystalline or solubilized in a matrix of an inert material(20). Solid
dispersions can broadly be classified as below
1. Eutectic mixtures: The two components are completely miscible in the liquid state
but partially miscible in the solid state;
2. Solid solution: The two components are completely dissolved and form a single
phase. The solid solutions are further classified as continuous and discontinuous
depending on the range of miscibility of the drug and the carrier materials;
3. Solid dispersions: Either amorphous or crystalline drug particles are dispersed
throughout the carrier matrix;
Although a lot of interest has been generated on the subject of solid dispersions there
are not many marketed formulations. This can be attributed to some of the known
3

challenges for formulation development using the solid dispersion approach such as
selection of manufacturing technique, reproducibility and scale-up of the manufacturing
process, maintaining the amorphous state during shelf life of the formulation and in
vitro/in vivo correlation. The carrier material is generally selected based on the chemical
structure of the drug and the manufacturing process used for solid dispersion
preparation. The carriers commonly selected for melt extrusion formulation development
are discussed in further sections.
Mechanisms of drug release
The most important advantage of solid dispersion formulation is apparent solubility
enhancement of water insoluble drug molecule. Reduction in particle size or changes to
the physical properties of the drug molecule are regarded as the main reasons for
increased solubility. Corrigan et al. showed correlation between dissolution rate of the
drug and dissolution rate of the carrier by separately measuring both(21). In the carrier
controlled drug release the dissolution rate of the drug is controlled by the dissolution of
the carrier material. The rate of dissolution can be described with the Noyes-Whitney
equation.
!"
!"

=!

!"!(!! !!)!

(1.1)

!

Where,
!"
!"

is the rate of dissolution, D is the diffusion coefficient, A is the surface area of the

solid, Cs is concentration of solid in the diffusion layer, L is the thickness of diffusion
layer.
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The dissolution rate of the individual component (drug or carrier) will affect the
composition of the diffusion layer which in turn dominates the drug release mechanism.
Craig et al. summarize the three scenarios of where the drug dominates dissolving
surface, carrier dominates dissolving surface and where both components dissolve in
the same proportion(22). The knowledge of the dissolution mechanism will assist in
prediction of the performance of a certain formulation. This could govern the selection of
carrier materials at early stages of formulation development.
Solid State Solubility
During solid dispersion formulation development, often the drug is regarded as a solute
and the polymer is considered as a solvent. The knowledge of solid state
solubility/miscibility of drug and polymer is imperative for successfully preparing a stable
formulation. Several theoretical as well as practical methods have been outlined for
prediction of drug-polymer solid state solubility. The theoretical approach for
solubility/miscibility determination is based on the solubility parameter approach.
Solubility parameter (δ) is defined as the square root of cohesive energy density.
References to this concept as early as 1916 are available however the symbol δ and
the current definition was proposed in 1949 by Hildebrand. This concept was refined
further by Fedors in 1974(23) exploring the additive properties of solubility parameter
showcasing the group contribution theory.
Although this solubility parameter is inclusive of energy contributions from the polar,
dispersive and hydrogen bonding effects, this approach was further extended into a 3
dimensional solubility parameters to separately account for energy contributions from
5

polar, dispersive and hydrogen bonding by Hansen(24). Further refinement of the
concept of 3-D solubility parameters was made by Hoy(25) and Hoftyzer-Van
Krevelen(26). It is generally considered that materials with close solubility parameter
values are likely to have high miscibility. The solubility parameter when used in
conjunction with the Flory-Chi parameter gives the ability to determine quantitative
values for solid state solubility limits of drug in polymer. Several researchers have
demonstrated the use of Flory-Chi parameters for estimation of solid state drug-polymer
solubility (27, 28).
The knowledge of the solid state solubility is beneficial for selecting drug loadings to
yield stable solid dispersions and to stay below the saturation solubility. This approach
reduces the time and resources required for development of formulation as it allows
strategic shortlisting of the carrier polymers based on the molecular structure of the
drug. Polymeric carriers that have a close structural similarity are likely to form
thermodynamically stable molecular dispersions with enhanced apparent solubility of
the drug molecule.
Hot Melt Extrusion (HME)
Hot Melt Extrusion (HME) has been explored as a tool to manufacture solid dispersions
and solid solution for over two decades (14). HME has numerous applications within the
pharmaceutical industry ranging from oral drug delivery applications such as solubility
enhancement(29), controlled release(30), taste masking(31) and enteric protection(32)
to manufacturing of implants for controlled parenteral drug delivery(33). There are
mainly two basic types of extruders: single screw extruders and twin screw extruders.
6

Twin Screw Extruders (TSE) are most commonly used in the pharmaceutical industry
and are available in a variety of manufacturing capacities(34). Most of the expertise
associated with operation of TSE has been adopted from the plastics industry which has
been continuously evolving for over 70 years(14, 35). Since its introduction in the
pharmaceutical industry, the TSE have been modified to adapt to the pharmaceutical
operation by using pharmaceutically compatible construction material like stainless
steel, modified fittings and cleaning components, use of approved lubricants and gear
oil as well as additional documentation for GMP qualification.
HME is a thermal process where the drug along with other excipients is intimately mixed
in the molten state. This technique has several advantages compared to traditional
pharmaceutical compounding techniques. HME is a series of unit operations where
feeding, mixing, melting, conveying and cooling takes place in a streamlined continuous
operation(36). HME also offers the ability to tailor the final product based on the dosage
form and intended application. One of the main advantages of HME is that the need of
solvents is completely eliminated. The molten polymer acts are a binder, solubilizer and
a vehicle during the manufacturing process. The intense heat and shear during the
extrusion process melts and solubilizes the crystalline drug which on cooling gets
entrapped in its most high energy amorphous state. Due to the nature of this process it
is not suitable for heat sensitive drugs however the formulation can be adjusted to bring
down the extrusion temperature.

7

Figure 1.1: Schematic representation of unit operations involved in a melt extrusion
process
Components of HME
An average extruder is composed of a feeder/hoper, single or twin screws, barrel to
hold the screws, heating elements, a die and a choice of downstream processing
equipment (Figure 1.1). Additionally an extruder may have heat and pressure sensors,
liquid/gas injection, additional feeding zones and Process Analytical Technology (PAT)
tools for in line monitoring of the process. PAT tools like Near Infrared (NIR) (37) and
Raman spectroscopy (38) have been used in conjunction with a TSE for in line
quantification of the drug levels as well as monitoring drug-polymer interactions taking
place inside the extruder
Extrusion process can be categorized as either a ram extrusion or screw extrusion. A
ram type extruder operates with positive displacement ram that generates high pressure
to push the molten material through a die whereas screw extruder has rotating screws
positioned inside a stationary barrel. The barrel itself has separate heating zones
8

designed to control the temperature of individual sections of the barrel. The barrel
temperature can impact the physical characteristics of the formulation and is selected
based on the thermal and chemical characterization of the ingredients (39).
Most extruder screws have configurable screw elements having either mixing or
conveying functions. Depending on the make and the model of the extruder, the
conveying elements may have different flight lengths. The mixing elements are
designed to generate intense shear and have maximum contribution to the overall
torque levels experienced by the machine. Therefore, it is important to ensure that the
temperature in the mixing region is sufficient to maintain appropriate viscosity of the
extruding material. The direction of the screws can be either co-rotating or counterrotating. Co-rotating extruders may have an intermeshing, self-wiping design and are
most commonly encountered in pharmaceutical industry as they can be run at high
speeds while maintaining the product quality. The counter-rotating TSE generate a high
amount of shear and works best in cases where intense mixing is desired(35). In
process torque generation is dependent on the screw configuration, screw rotational
direction and speed, melt viscosity of the material and extrusion temperature.
The geometry of an extruder is defined in terms of its length to diameter ratio and typical
extruder L/D ratios are in the range of 20 to 40:1.The length of the extruder along with
the screw speed directly affects the residence time. Average residence time in the
extruders can vary between 5 sec to 10 min depending on the operating conditions.
Scale-up of extrusion process to an extruder with similar geometry is relatively easy(40).
Theoretical values of the barrel temperature, screw speed and feed rate can be
9

calculated

based

on

equations

based

on

specific

mechanical

energy

calculations(41).Scale-up of pharmaceutical melt extrusion process and its influence on
the formulation characteristics have been investigated by Guns et al(41).
Several choices of downstream processing equipment are available to use with the melt
extrusion process. The molten material can either be pushed through a die to yield
films, rods or pellets or it can be injection molded into any desired shape. Specially
designed melt extrudates have been prepared for transmucosal, buccal, vaginal and
transdermal drug delivery. Often, melt extrudates are milled to fine powder mixed with
other excipients and either filled into capsules or compressed into tablets for
conventional pharmaceutical solid dosage.
Formulation Development for HME
Selection of carrier material
Along with appropriate processing conditions, selection of excipients is very important to
success of a HME formulation and efficiency during manufacturing. Several
pharmaceutically compatible carriers are available to use with the melt extrusion
process. The main characteristics of a carrier material are: it should be inert, melt at a
low temperature, stable over the shelf life of the product, cheap and easily available.
Polymers from a wide range of chemical classes are available to select from. The
selection of polymers for HME formulation may be based on the chemical structure of
the drug as well as intended final application of the product. Low molecular amorphous
polymers such as Polyvinyl pyrollidones (PVP) or polymethacrylates may be selected
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for immediate release formulations whereas high molecular weight cellulosic polymers
may offer good sustained release. Use of wax as a matrix former for controlled release
of diclofenac is reported by Miyagawa et al(42).
Polymethacrylate

polymers

are

synthetically

derived

polymers

based

on

dimethylamioethyl methacrylate, methacrylic acid and methacrylic acid esters. These
polymers have glass transition temperatures ranging from 40 to 140°C depending the
grade.

Eudragit®

E

PO

(Figure

1.2)

is

a

cationic

pcopolymer

based

on

dimethylaminoethyl methacrylate chemistry and is soluble up to a pH 5.0. Eudragit® RS
and RL (Figure 1.3) are pH independent polymers based on ethyl acrylate, methyl
methacrylate methacrcrylic acid ester chemistry. Eudragit® L 100-55 (Figure 1.4) is an
anionic polymer based on methacrylic acid and ethyl acrylate chemistry with dissolution
above pH 5.5. Several applications of polymethacrylate polymers in HME are recorded
for immediate release(31), controlled release(30), enteric protection(43) as well as taste
masking(44).

Figure 1.2: Molecular Structure of Eudragit® E PO
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Figure 1.3: Structure of Eudragit® RL PO- x:y:z ! 1:2:0.2 and Eudragit® RS PO- x:y:z
! 1:2:0.1

Figure 1.4: Molecular Structure of Eudragit® L 100-55
Polyethylene oxide (PEO) (Figure 1.5) polymers are semi-crystalline polymers
synthesized by heterogeneous catalytic polymerization of ethylene oxide monomers.
Depending on the molecular weight the melting temperature may range between 55 to
75°C. Their applications as HME carrier materials have been investigated but additional
antioxidants and crystallization inhibitors are needed for stabilization of the
formulation(45).

12

Figure 1.5: Molecular structure of Polyethylene Oxide
Cellulose based polymers are derived from naturally occurring cellulose in the plant
cells. Several types of cellulose based polymers have been investigated for HME
formulation development including Hydroxypropyl Cellulose (HPC), Hydroxypropyl
Methyl Cellulose (HPMC) (Figure 1.6), Ethyl Cellulose (EC) and Hydroxypropyl Methyl
Cellulose Acetate Succinate (HPMCAS. These polymers have been explored as HME
carriers for immediate release(46), controlled release(47) and muco-adhesive film(48)
formulations.

Figure 1.6: Molecular Structure of Hydroxypropyl Methyl Cellulose
PVP based polymers are synthetic polymers derived from vinyl pyrolidone and have
been utilized as carriers for melt extrusion technology. They have been investigated as
carriers for immediate release formulations (17, 49). Kollidon® VA 64 (Figure 1.7) and
Soluplus® are some of the commonly used pharmaceutical polymers belonging to this
class. Being a relatively new product, applications of Soluplus® for solubility
enhancement are still being evaluated and currently it is not a part of any approved
product.
13

Figure 1.7: Molecular structure of Kollidon® VA 64
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Table 1.2: Commonly used carriers for HME formulations
Chemical Name

Trade Name

Tg (°C)

Tm (°C)

Ammonio methacrylate copolymer

Eudragit® RS/RL

63 - 68

--

Poly(dimethylaminoethylmethacrylateco-methacrylic esters)

Eudragit® E

45 - 48

--

Poly(methacrylic acid-co-methyl
methacrylate) 1:2

Eudragit® S/L

160

--

Cellulose Acetate Phthalate

--

165

192

Poly(vinyl pyrrolidone)

Kollidon®

90 - 156

--

Hydroxypropyl Methylcellulose
Phthalate

--

137

150

Polyvinyl pyrrolidone-co-vinyl acetate

Kollidon® VA64

101

--

Polyvinyl caprolactam-polyvinyl
acetate-polyethylene glycol graft
copolymer

Soluplus®

70

--

Hydroxypropyl Methylcellulose (HPMC)

Methocel®,
Benecel®

160 - 210

--

HPMC Acetate Succinate

Aqoat-AS®

~ 120

--

Ethyl cellulose

Ethocel®
Aqualon® EC

130 - 133

--

Hydroxypropyl Cellulose

Klucel®

~130

--

Polyethylene Glycol

Carbowax®

-17

37- 63

Polyethylene Oxide

PolyyOx® WSR

-57 - 50

62 - 67

Carnuba Wax

---

81 - 86

--
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Processing Aids
As with any pharmaceutical process there may be a need for additional processing aids
to increase the efficiency of the HME process. Plasticizers are generally required for
high molecular weight, high melt viscosity polymers to bring the processing temperature
down. Plasticizers are low molecular weight compounds with low Tg that reduce the
overall softening temperature of melt. Depending on the hydrophilic or hydrophobic
nature of the plasticizer it may have a positive or negative effect on the drug release
rate. Plasticizers also assist in reducing the brittleness of the HME films thereby
increasing the strength.
In order for a material to work successfully as a plasticizer, it should be compatible with
the drug and the carrier material used and be stable over the shelf life of the product.
Citrate esters, fatty acid esters, sebacate esters, phthalate esters, glycol derivatives,
mineral oil, castor oil and Vitamin E TPGS derivatives have been explored as
plasticizers for HME process. In some instances where the Tg of the drug molecule is
low, it can act as a plasticizer. Wu et al. reported the use of ibuprofen as a solid state
plasticizer for extrudates prepared with Eudragit® RS PO(50). Formulation stability
testing is recommended when working with plasticizers as due to the low molecular
weight of the plasticizers there is a likelihood of the molecules leaching out over time
thereby compromising the performance of the formulation. Additional processing aids
such as anti-oxidants, preservatives, crystallization inhibitors, complexing agents,
lubricants, anti-tacking agents may be necessary to cater specific needs of the drug
molecule(36).
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Analysis of Melt Extrudates
Based on the thermo-mechanical properties of polymers, they are commonly classified
as thermoplacstics, elastomers and thermosets. Owing to their linear nature,
thermoplastics deform and flow when heat is supplied and will retain any shape as they
cool. Most polymers selected for pharmaceutical melt extrusion belong to this category.
Thermosets and elastomers due to their cross-linked nature retain the shape that they
were manufactured for the first time forming a cross linked network. Due to these
properties, thermosets and elastomers have limited pharmaceutical melt extrusion
applications(26).
Thermoplastic polymers can either be crystalline, amorphous or partially crystalline in
nature. The crystallinity is associated with a long range three-dimensional order arising
from the arrangement of the macromolecular chains. Amorphous polymers are hard and
brittle at temperatures below their glass transition temperatures (Tg) whereas soft and
pliable at higher temperatures. The glass transition temperature can be determined by
either thermal or thermo-mechanical methods. Partially crystalline polymers like
Polyethylene oxide may exhibit both a melting point (Tm ) as well as a Tg. Below the
glass transition temperature, the movements of the chain segments vibrate around fixed
positions. When the temperature increases, the amplitude of the vibrations increases
and the rise in tension is translated to the intermolecular interactions. On further
increase in the temperature, a fraction of the chain segments acquire enough energy to
overcome these interactions. The glass transition temperature is the critical temperature
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at which the molecular mobility can be detected. The glass transition temperature also
affects the shelf stability of the melt extruded formulation.
Melt extrusion experiments are performed at a temperature above the glass transition
temperature of the polymeric carrier to ensure that the dry physical mixtures are
sufficiently molten to allow for intimate mixing. Addition of drug, plasticizer and other
processing aids may alter the range of the glass transition temperature. The final Tg of a
formulation may be a result of additive effects from all the components and their
proportions in the final mixture. The well-known fox equation has been demonstrated for
prediction of Tg of a mixture based on the Tg of the individual components and their
molar ratio in the mixture(51).
!
!!

=!

!!
!! ,!

+!
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(1.2)

!! ,!

Where, !! and !! are weight fractions of components 1 and 2 respectively.
During development of a solid dispersion formulation it is necessary to characterize the
physical state of the drug, in vitro and in vivo performance as well as shelf stability of
the prepared formulation. Several analytical techniques have been utilized for
characterization of solid dispersion formulations as discussed below.
1. Differential Scanning Calorimetry (DSC)
DSC is a thermo-analytical technique which quantifies the amount of heat required to
increase the temperature of a sample in comparison to a reference. The sample and
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reference both are contained in identical aluminum pans that have the capacity for
hermetic sealing. The samples are heated at a constant heating rate and the heat
required to maintain constant temperature is recorded. Both high and low heating rates
have been utilized for characterization of solid dispersions. The lower heating rates yield
accurate melting point temperature measurement whereas the higher heating rates
have been demonstrated as a tool to measure the solid state drug-polymer solubility(52,
53). DSC is the most commonly used tool to determine the glass transition temperature
of pure polymers as well as polymer mixtures(54). Although widely used for
characterization of the physical state of the drug, DSC has several limitations.
Conventional DSC falls short when analyzing materials with overlapping melting or
transition events. Moreover, DSC cannot detect trace amount of crystalline phase
therefore is often used in conjunction with XRPD analysis.
2. X-Ray Powder Diffraction (XRPD)
XRPD is a tool used for detection of crystalline phase in a sample utilizing the
relationship between density of the material and absorption of X-rays. During XRPD
measurement, the sample is subject to a beam of x-ray. The crystals in the samples
diffract the x-ray in a characteristic pattern whereas an amorphous sample does not
exhibit a diffraction pattern. XRPD is often utilized in conjunction with DSC to detect
trace amount of crystalline phase. XRPD is an important tool during solid dispersion
formulation development due to the accuracy of detecting phase change. A main
disadvantage of using XRPD for melt extruded formulations is that the physical form of
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the formulation is disturbed when milling in to a powder potentially changing the delicate
thermodynamic balance.
3. Thermogravimetric analysis (TGA)
Due to the inherent nature of the melt extrusion process, thermal characterization is an
important preformulation consideration. TGA analysis measures loss in weight of a
preweighed sample as the temperature of the sample chamber is elevated at a constant
rate(55). An additional application of TGA is to analyze the volatiles released from a
sample upon heating.
4. Fourier Transform Infrared Spectroscopy (FTIR)
All chemicals exhibit characteristic IR spectra which have been used for identification,
quantification and analysis of pure materials and mixtures. The FTIR spectra is
generated from the chemical structure of a compound through the characteristic
absorption bands associated with vibration of atoms in the infrared region. FTIR is often
used to detect intermolecular interactions during melt extrusion processing. The shift in
the absorption wavelength or appearance/ disappearance of characteristic peaks can
allow investigators to identify potential molecular interactions(56).
Quality by Design
Quality by Design (QbD) is an initiative by the Food and Drug Administration (FDA) to
harmonize the process for new and generic drug applications. QbD is defined as “A
systematic approach to development that begins with predefined objectives and
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emphasizes product and process understanding and process control, based on sound
science and quality risk management”(57). Pharmaceutical QbD requires a thorough
understanding of the product and the process along with the knowledge of the
relationship between the Critical Quality Attributes (CQAs) and the clinical performance
of the product. The effect of individual process parameters on the final product’s CQAs
is studied with the help of statistical Design of Experiments (DoE) through which an
operational Design Space (DS) is established. As a result of this, a range of variability is
defined for each variable under which the CQAs remain within the pre-established
limits. Thus a controlled DS is generated for the process. Although adapting QbD
methodology initially may be thought to be cumbersome, it eventually means less
paperwork and resources when a change needs to be introduced in the manufacturing
process. It will also reduce overall waste produced during manufacturing as well as
allow efficient globalization for companies with manufacturing sites across the
world(58),(59).
QbD has been developed with an approach to improve the efficiency of the entire drug
manufacturing and filing process. A typical QbD study has the following steps: 1.
Establishment of Quality Target Product Profile, 2. Risk Assessment, 3. Screening and
Optimization studies, 4. Generation of Design Space and 5.Control Strategy(57). A
schematic for process development using implementation of QbD principles is
presented in Figure 1.8. Application of QbD concept has been published for several
pharmaceutical techniques such as fluid bed granulation(60, 61), spray drying(62, 63),
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tablet compression (64, 65), liposomes(66, 67), sterile products(68) and gel
manufacturing(69).

Quality%Target%Product%Profile
Ishikawa(Diagram
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Development
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Screening(Design

Formulation(
Optimization
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Measurement%of%CQAs

Optimization(
Design

Data%Analysis%and%Design%Space%
Generation

Figure 1.8: A schematic representation of process development using the QbD
approach
Establishment of Quality Target Product Profile (QTPP)
The QTPP outlines the specifications of the final product that are essential to be built
into the product during the developmental stage. This describes the profile of the
product with respect to the physical appearance, assay, dosage strength, container
enclosure system, pharmacokinetic characteristics as well as in vitro and in vivo
performance. This profile acts as guidance throughout the product development phase.
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Critical Quality Attributes (CQAs)
A CQA is defined as “any physical, chemical, biological or microbiological property that
should be within an appropriate range limit or distribution to ensure the desired product
quality”(57). CQAs are measurable product attributes that can be derived from the
QTPP or prior knowledge of the product. For a solid dosage form like tablets the CQAs
can be tablet hardness, friability, disintegration time, assay, dissolution time. A CQA can
also be an esthetic attribute of the product such as the physical appearance like color,
size and shape of the logo, glossiness and so on. Additional CQAs from the
manufacturing process such as curing time, temperature and feed rate may be
considered for monitoring during the product development phase.
Risk Assessment
Out of the hundreds of factors potentially affect a pharmaceutical process, it is often
difficult to select the most important factors. Risk assessment is a scientific tool for
systematically shortlisting and prioritizing the factors that potentially have an impact on
the CQAs. While there are several risk assessment tools available to use, the most
commonly used techniques include construction of the fishbone (or Ishikawa) diagram
and Failure Mode Effect Analysis (FMEA). Ishikawa diagrams were created by Kaoru
Ishikawa to show the causes associated with a particular event(70). The causes are
separated based on their source and each arm highlights causes associated with that
particular source. The commonly addressed sources are people involved with the
process, plant environment related factors, methods used for manufacturing, use of
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specific machinery and equipment, source and nature of raw materials and analytical
methods.
The FMEA analysis is a tool to systematically analyze all the factors that potentially
affect the product development. In a FMEA study, all possible factors are listed down as
failure modes. The parameters listed in an FMEA study can be related to the process as
well formulation. An interdisciplinary team of experts then grades each failure mode
based on its occurrence, detectability and severity. Each failure mode is given an
average score for each individual category and a product of these scores is further used
to generate a Risk Priority Number (RPN). These failure modes are prioritized based on
their RPN score and failures with the highest RPN are likely to cause a significant
impact on the CQAs of the product. The shortlisted factors are then considered for a
DoE based screening and optimization study.
Design Space
The DS is defined as “the multidimensional combination and interaction of input variable
and process parameters that have been demonstrated to provide assurance of
quality”(57). The parameters shortlisted in the risk assessment stage are further
quantitatively analyzed using a DoE study. This also could be an opportunity for
investigators to determine the levels of processing aids such plasticizer, glidants,
antitacking agent at which optimum performance is achieved. Generally a full factorial or
an Response Surface Model (RSM) is then employed to investigate the significance of
each parameter in the study. The CQAs such as the dissolution rate, tablet hardness,
disintegration time, assay and drug content uniformity are measured as responses.
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Data analytical techniques like multi linear regression or partial least squares are then
utilized for generating predictive models for measurement of individual responses. The
analysis of the DoE study culminates into a DS that describes the relationship between
process inputs (CPPs) and the measurable final product attributes (CQAs). A DS may
be described in terms of the ranges of material attributes and process parameters or
through complex mathematical relationships. A change of manufacturing conditions
within the predefined design space does not require additional documentation and filing.
Control Strategy
After the initial processing ranges have been established and proven to yield the
desired values of CQAs, a control strategy is designed to ensure that the product quality
will be maintained. During development of control strategy, sources of variation are
identified and their effect on the final product attributes are outlined. Control strategy
may be designed to monitor the specifications of the incoming materials, unit operations
during manufacturing, as well as real time testing. A control strategy can employ in line
monitoring tools to monitor product attributes during manufacturing. This will facilitate in
addressing potential failures before they occur.
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CHAPTER 2
OBJECTIVES
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1.

To evaluate application of solubility parameter theory for excipient
selection for HME formulation development
a. To theoretically predict the solubility parameters of ibuprofen and each of the
carrier polymer selected based on the group contribution theory and the
molecular structure.
b. To measure the experimental solubility ranges using film casting and melt
extrusion
c. To demonstrate advantage of amorphous solid dispersions in vitro by
performing dissolution experiments

2.

Thermal and chemical characterization of Ibuprofen-Eudragit® E PO solid
dispersions prepared by HME
a. Prediction of phase diagram based on the Flory-Chi theory outlining the
temperature – composition relationship
b. Evaluate

and

investigate

molecular

interactions

using

spectroscopic

techniques
c. Study the stability of the prepared melt extrudates at room temperature
3.

Application of Quality by Design (QbD) approach for product development
using HME
a. Perform qualitative risk assessment by plotting the Fishbone diagram and
Failure Mode Effect Analysis
b. Perform quantitative risk assessment using a Placket-Burman experimental
screening design
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c. Analysis of the critical factors in a complete experimental design
d. Prediction of the design space based on the analysis of the response values
4.

Evaluation of drug release mechanism of Ketoconazole – Kollidon® VA 64
melt extrudates
a. Preparation and analysis of melt extrudates
b. Investigate the swelling and erosion behavior of the prepared extrudates
c. Determine the drug release mechanism based on in vitro dissolution studies
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CHAPTER 3
POLYMER SCREENING APPROACHES FOR FORMULATION DEVELOPMENT
USING MELT EXTRUSION
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Introduction
Solubility enhancement with the aid of solid dispersion formation has continued to be a
topic of interest within the pharmaceutical industry and academia (18, 71). To become
bioavailable, a drug should be soluble in gastrointestinal fluids and also be permeable
through the cell membranes in the intestine. Solid dispersions offer the ability to freeze
the drug molecule in its highly soluble amorphous form thus increasing the solubility and
most likely the bioavailability of the drug (72).
Pharmaceutical Hot Melt Extrusion (HME) is a thermal technique that involves mixing of
the drug and polymeric excipients at temperatures above the Glass Transition (Tg) of
the polymer thereby solubilizing the drug in the polymer(72). HME has gained significant
momentum in recent years within the pharmaceutical industry for manufacturing solid
solutions with enhanced solubility addressing the bioavailability issues of increasing
number (~70%) of BCS II and IVNDAs (New Drug Applications) in the current R&D
pipelines(3).
Solid solutions are formed when there is significant structural similarity between the
polymer and the drug. The drug-polymer miscibility has been estimated using
theoretical (23, 73-76) approaches where the cohesive energy densities corresponding
each individual functional group in a molecule is accounted towards calculation of the
total solubility parameter of the molecule. Extending this method, researchers have
determined individual energy contribution from the polar, dispersive and hydrogen
bonding forces (26). Such computationally calculated 3-D solubility parameters and their
application in developing stable solid solution formation has been evaluated (76, 77).
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Experimental approaches for solubility determination include melting point depression
(27,

28),

annealing(78),

diffusion

based(79),

determination

of

drug-monomer

solubility(80) and inverse gas chromatography(81). Knowledge of the drug-polymer
miscibility values facilitates in selecting appropriate functional excipients to achieve the
desired in vivo release profile. Depending on the choice of the excipients a wide range
of dissolution profiles for immediate release as well as modified release can be
accomplished using HME (39, 73, 82).
Traditionally a more time consuming, trial and error based method is employed in which
several excipients are screened in the laboratory. Efforts to expedite this process using
automated robotic systems have been evaluated(82-84). These techniques demand
specialized equipment, high amount of drug and therefore may not be always practical.
Solubility prediction methods can be used as screening tools to shortlist the chemically
most compatible polymeric carriers for a given drug component and thereby reduce the
number of experimental trials. To increase chances of solubility enhancement using
solid solution formation, it is important that the drug is maintained in its high energy
amorphous form(18). Solid solution can be formed by ensuring that the concentration of
the drug is below the saturation solubility (Cs) of the drug in given polymer. For this
reason, it is important to know the solubility of the drug in the polymeric carrier in
consideration.
The objective of the present study was to evaluate the application of solubility
parameters for selection of excipients for solid dispersion formulation development
using melt extrusion. 3-D solubility parameter values for Ibuprofen and each polymer
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selected for this study is predicted using Hoftyzer/Van Krevelen method that accounts
for polar, dispersive and hydrogen bonding forces separately(26). Recently, after
comparing theoretical and experimental solubility parameters, researchers have
concluded that these conventional solubility parameter techniques are more accurate
for common polymers(85). The difference in the solubility parameter gives an indication
of miscibility of the two components. These ranges are then verified experimentally
using film casting and melt extrusion experiments. A fourth type of force ie ionic
interactions are studied separately experimentally in chapter 4. Ibuprofen a weakly
acidic, non-steroidal anti-inflammatory drug categorized as BCS class II having a
melting point (Tm) in the range of 75 to 77°C is used as a model drug for solubility
determination. Eight pharmaceutical grade polymers with distinct chemistry were
selected for the screening studies.
Materials
Ibuprofen (Albemarle, USA; BCS Class II) was used as model drug in this study.
Plolymers EUDRAGIT® E PO, EUDRAGIT® L 100-55, EUDRAGIT® RL PO and
EUDRAGIT® RS PO were obtained from Evonik Pharma Polymers (Evonik Corporation
Piscataway, NJ, USA), HPMCAS-LF was obtained from Shin Etsu (Tokyo, Japan),
Kollidon® VA 64 and Soluplus® were obtained from BASF specialty chemicals
(Ludwigshafen,Germany). HPMC E5 was obtained from Dow Chemical (Midland,
Michigan, USA). All polymers were used as received. Ibuprofen was sieved with a USP
#35 screen to remove agglomerates. USP grade 190 proof ethanol purchased from
Fisher Scientific was used as a solvent for film casting.
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Methods
Solubility Parameter Calculation
The solubility parameter (δ) is a measure of cohesive energy density (Ecoh) per unit
volume of a material. The Ecoh represents the total attractive forces within a condensed
state of the material and can be defined as the amount of energy needed to separate
the atoms/molecules to a distance where no interactions occur. Solubility parameters for
ibuprofen and all polymers were calculated using the group contribution method outlined
by Fedors which was later expanded by Hoftyzer-Krevelen (23, 26). The solubility
parameters for polymers were calculated in two steps 1- calculation of solubility
parameters of individual monomers and 2- calculation of solubility parameter of
polymers based on proportional average of the monomers components.
3D solubility parameters were originally defined by Hansen where the energy
contribution from dispersion, polar and hydrogen bonding are separately calculated
based on the molecular structure(24). Hansen defines the total solubility parameter as
!!"# = ! !! + !! + !!

(3.1)
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(3.2)

Where, subscript d stands for dispersive forces, p stands for polar forces and h stands
for hydrogen bonding energy from self-association of the molecule. Contributions
associated with dispersive, polar and hydrogen bonding forces were individually
calculated using the following equations.
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Based on the theory that ‘like dissolves like’, it is generally considered that materials
with closely related solubility parameters are miscible. A drug is considered miscible in a
polymer if the difference in their solubility parameter is less than 7 (δd- δp < 7) (73, 86).
Film Casting
Accurately weighed drug-polymer mixtures with the desired drug load (Total wt: 1.00
gm) were dissolved in 30 mL ethanol using a magnetic stir station and allowed to
equilibrate for 24 hrs. The resultant clear solution was transferred in a glass petri-dish
and allowed to dry in a fume hood and tested for absence of solvent using a loss on
drying apparatus. The prepared films were stored in air tight clear storage bags until
further testing.
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Figure 3.1: Structures of drug and polymers used in this study
Melt Extrusion
Binary mixtures of Ibuprofen with each polymer were prepared by weighing individual
components and blending using a Turbula T2F shaker mixer (Glen Mills Inc.Clifton, NJ)
for 10 min to ensure homogenous mixing. The mixtures were extruded using a 16mm
co-rotating twin screw extruder (Leistritz Coporation, Allendale, NJ) complete with a
bottom plunger feeding assembly and a 4mm round die. The four heating zones for this
extruder equipment were set to 70, 140, 140, 140 °C however due to the plasticizing
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effect of Ibuprofen(87) temperatures needed to be lowered for high drug load
formulations. Extrusion screw rotation speed (150 rpm) and the feed rate (5cc/min) were
maintained constant for all the batches. The extruded material was allowed to cool on a
conveyor belt (Dorner, Hartland, WI) supplied with a jet of cool air and stored in airtight
containers in a dark cabinet until further processing. All samples were milled using IKA
A11 basic analysis mill and sieved through a USP #35 mesh screen. A small portion of
the extrudate was flattened between two glass slides for microscopic analysis. The
screws were pulled out and the barrel was cleaned after each set of formulations.
All samples were milled using IKA A11 basic analysis mill and sieved through a 35
mesh screen. Any material that did not pass through 60 mesh screen was transferred
back in IKA A11 to be milled and sieved again. This process was repeated until all
material passed through 60 mesh screen. The material that did not go through the sieve
was stored separately and used for further analysis. The fines were eliminated by
sieving through a screen with mesh number 200.
Differential Scanning Calorimetry
Differential scanning calorimetric analysis was performed on the milled extruded
samples using a Pyris 6 DSC (PerkinElmer, Waltham, MI). 8 – 10 mg of the milled
extrudate was weighed, crimped in an aluminum pan. The samples were heated to
100°C at 20°C/min, cooled to 0°C and heated to 120°C at 20°/min under nitrogen purge
of 20 ml/min.. The first heating eliminated the thermal history and moisture whereas the
second heating facilitated in the determination of Tg. Samples with increasing ratio of
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ibuprofen were analyzed and the ratio at which crystalline phase of ibuprofen could be
detected was noted.
Microscopy
Optical analysis were performed on the film casted and extruded samples using an
Olympus BX51 microscope (Center Valley, PA)c coupled with polarized filters to
evaluate the drug’s physical state. A drug-polymer film is placed between two glass
slides and observed with transmission mode under polarized light. The samples were
stored at room temperature (25±2.5°C) and examined for recrystallized drug crystals
periodically up to 1 year.
Dissolution Testing
The milled sample (equivalent to 200mg of ibuprofen) was filled in a size 00 clear
capsule. Dissolution on the filled capsules was performed (n=3) using USP apparatus 2
with a Varian VK 750 D dissolution equipment, at 37ºC and with a stir speed of 50 rpm
in two media pH 1.2 and pH 6.8 separately. Dissolution samples were withdrawn using
a Varian auto sampler connected to a spectrophotometer. A control sample, where
200mg of pure drug was placed in a size00 clear capsule was used for comparison. The
dissolution profiles obtained for ibuprofen samples were compared to that of marketed
Ibuprofen soft gelatin capsules and IR tablets both with a dose of 200mg.
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Results and Discussion
Solubility Parameter Calculation
The use of solubility parameters as tools to predict compatibility between drug/polymer
systems have been demonstrated for many pharmaceutical systems(23, 73, 86, 88).
The most common method used for calculation of solubility parameters is by using the
group contribution theory developed by Hildebrand(89). This approach was further
extended to separately calculate the contributions from hydrogen bonding, polar and
dispersive forces(24, 26).

In this study, structure of model drug ibuprofen was

defragmented into individual functional groups in order to determine the Hildebrand
Solubility Parameter including the individual contributions corresponding to hydrogen
bonding, polar and dispersive forces using the Hoftyzer-Van Krevelen method(26).
Figure 3.2 shows defragmentation of the molecular structure of Ibuprofen and the
groups that were used for solubility parameter calculation by group contribution method.
Cohesive energies associated with each group were added to calculate the total
cohesive energy Ecoh for the entire molecule. The solubility parameter was then
calculated based on the equation 3.2. Similar method was applied to calculate the
solubility parameters of monomers. The solubility parameter of the polymer δpoly was
then calculated by taking proportional average of individual monomers.
The cohesive energy is the summation of all the molecular interactions including
dispersive, polar, hydrogen bonding as well as the ionic interactions. Compounds with
similar cohesive energies are likely to be miscible with each other. If the difference in
solubility parameters of the drug and that of the polymer is less than 7 (δp-δd) then the
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two are generally considered to be miscible(86). Several researchers have explored use
of solubility parameters approach to determine drug/polymer miscibility and solubility
(53, 73, 74, 78). The calculated solubility parameter and miscibility estimations in terms
of difference in solubility parameter for ibuprofen and each polymer considered in this
study is given in Table 3.1. The lower values of δp-δd indicate higher miscibility. In the
case of ibuprofen, the higher miscibibility is expected for Eudragit® E PO, Eudragit® L
100-55, Eudragit® RS PO, Eudragit® RL PO, Kollidon® VA 64 and Soluplus® whereas
borderline miscibility is expected in polymers HMPCAS-LF and HPMC.
Bagley et al observed the similarities between δd and δp and derived the following
expression(90)

!
!! ! = ! !!!
! +!!! !

(3.6)!

A plot of δv and δh can outline the compatible solvents for a certain drug molecule based
on the chemical structure of the drug and the polymers. Such a diagram for ibuprofen
and the polymers considered in this study is shown in Figure 3.3. The circle represents
an approximate delimited region of solubility for ibuprofen. It can be seen that the
predictions based on the difference in solubility parameter are further confirmed using
the δv- δh plot. These estimations are further verified using experimental techniques.
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Figure 3.2: Molecular Defragmentation of Ibuprofen Structure
Table 3.1 Difference in solubility parameter of the drug and polymer
Solubility Parameter (δ)

|δp-δd|

Ibuprofen

18.98

NA

®

21.40

2.42

®

19.77

0.79

®

Eudragit RS PO

21.61

2.63

Eudragit® RL PO

21.53

2.55

Kollidon® VA 64

26.12

7.14

Soluplus®

22.97

3.99

HPMC

37.51

18.53

HPMCAS-LF

36.23

17.25

Eudragit E PO
Eudragit L 100-55
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Experimental Solubility
To further test the reliability of this predicted miscibility approach, the ranges of solubility
were determined experimentally using ethanol casting and melt extrusion using various
drug loads. Spray drying and melt extrusion are two commonly used techniques for
manufacturing of solid dispersions. Due to the solvent interactions involved, results
obtained from ethanol casting are likely to be comparable to solid dispersion
manufacturing techniques like spray drying where the effects of solvents need to be
taken into consideration. Melt extrusion experiments were conducted for each polymeric
excipient with varying ibuprofen concentrations. The extrudates were analyzed using
DSC and microscopy to identify recrystallization. Table 3.2 compares the predicted and
the experimental solubilities of ibuprofen in select pharmaceutical polymers.
Extrudate Analysis
DSC studies were conducted for characterization of the physical state of the drug. The
change in the enthalpy due to melting of the crystalline drug results in a characteristic
melting event in the DSC thermogram. In absence of a crystalline drug no such event
was observed. Samples with increasing ibuprofen loading were screened and compared
with a thermogram of a blank polymer sample. The concentration at which a melting
event could be seen was regarded as the saturation solubility of the drug in the polymer
solvent. DSC scans for melt extrudates of ibuprofen with each polymer are presented in
Figure 3.12. The saturation solubility values obtained from the DSC studies were further
confirmed with microscopic examination of the films.
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Figure 3.3: δv – δh diagram showing solubility of Ibuprofen in selected polymers

Figure 3.4: DSC thermograms of Ibuprofen- Eudragit® E PO melt extrudates
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Figure 3.5: DSC thermograms of Ibuprofen- Eudragit® L 100-55 melt extrudates

Figure 3.6: DSC thermograms of Ibuprofen- Eudragit® RS PO melt extrudates

43

Figure 3.7: DSC thermograms of Ibuprofen- Eudragit® RL PO melt extrudates

Figure 3.8: DSC thermograms of Ibuprofen- HPMCAS-LF melt extrudates
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Figure 3.9: DSC thermograms of Ibuprofen- HPMC melt extrudates

Figure 3.10: DSC thermograms of Ibuprofen- Soluplus® melt extrudates
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Figure 3.11: DSC thermograms of Ibuprofen- Kollidon® VA 64 melt extrudates
Polarized light is reflected by crystals present in the study sample thus making detection
of crystals easy. The optical microscopic analysis performed on the samples allowed
detection of recrystallization in the solid solutions prepared by film casting and HME.
Microscopic analysis was performed to verify the results of the DSC scanning. In certain
instances when the percent crystallinity is low, the DSC thermograms may not detect
enthalpy associated with crystallization. An amorphous solid solution appears black
under polarized light (Figure 3.12) and the crystals appear luminescent making them
easy to identify (Figure 3.12 (b)). From the DSC and microscopic results, a range of the
solubility/miscibility of drug in each of the polymeric matrix was obtained. These
experimental solubility ranges for all the samples is given in Table 3.2 in comparison to
the predicted miscibility ranges based on difference in the calculated solubility
parameter.
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(a)

(b)

Figure 3.12: Ibuprofen -Eudragit® E PO melt extrudate under polarized light (a) 55%
ibuprofen (b) 70% ibuprofen
Table 3.2: Comparison between predicted and experimental solubility values
Polymer

Predicted miscibility

Film Casting

HME

Eudragit® E PO

High

65

65

Eudragit® L100-55

High

7.5

35

Eudragit® RL PO

High

27.5

25

Eudragit® RS PO

High

27.5

25

HPMCAS-LF

Low

25

25

HPMC-E5

Low

12.5

15

Kollidon® 64

High

55

55

Soluplus®

High

25
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Evaluation of Solid Dispersions prepared by HME
The prepared melt extrudates were evaluated for solubility enhancement using in vitro
dissolution apparatus. For each polymer, formulations with ibuprofen concentration
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below the maximum solubility were selected for dissolution testing therefore the drug
was in the amorphous form in all the formulations. Being a weak acid, Ibuprofen shows
pH dependent solubility. Practically no drug release was observed in the pH 1.2 media
except for the Eudragit® E PO formulation, where the release 3 folds higher when
compared to the pure ibuprofen as well as the standard ibuprofen tablet and soft gel
formulation (Figure 3.13). This increase in dissolution can be attributed to the formation
of ionic interactions between the anionic drug and the cationic polymer and is further
investigated in chapter 4 of this document. It has been reported by Jamali et al. that
increase in the dissolution at the gastric pH overall increases the drug absorption across
the gastro-intestinal tract(91).As soon as the pH of the media is switched to 6.8 the
ibuprofen control releases 90% within the first 60 minutes (Figure 3.14). At this pH, the
influence of the properties of the carrier polymer on the release profile is evident.
Release from the melt extruded formulations appears to be slower due to the fact that
additional time is required for polymer dissolution and matrix erosion.
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Figure 3.13: In vitro dissolution of prepared ibuprofen melt extrudates with individual
polymers at a concentration below the maximum solubility in pH 1.2
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Figure 3.14: In vitro dissolution of prepared ibuprofen melt extrudates with individual
polymers at a concentration below the maximum solubility in pH 6.8
Conclusion
In summary, this study compares the predicted miscibility ranges based on the
molecular structure with the actual experimental values obtained from the film casting
and HME experiments. Theoretical solubility prediction has several limitations due to the
fact that it does not consider the steric and isomeric hindrances as well as interactions
introduced due to the processing factors like heat, torque or solvent related interactions.
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In spite of these limitations, this method provides a reasonable alternative to expensive
and time consuming experimental screening and provides a starting point for short
listing of suitable excipients. The predicted values were in accordance with the
experimentally determined ranges of solubility. The solubility parameter concept does
not account for ionic interactions between the drug and the polymer that may explain
the discrepancy in experimental and predicted solubility levels for ionic polymers like
Eudragit® E PO. The solubility of drug in polymer ranking order is supported with
experimental data.
Solubility parameters can aid in selection and shortlisting of excipients for a HME
formulation and can generate miscibility profiles for an API with commonly available
pharmaceutical polymers if the chemical structures are known. In this study, the use of
solubility parameter concept in selection of excipients for a model drug ibuprofen was
demonstrated. Such methods will reduce the time and resources required during the
initial stages of product development. This approach for polymer screening is intended
to serve as a starting point for experimental trials followed by further in depth analysis
and may also serve as a guide in selection of specific functional excipients for enteric,
sustained and modified release applications. Knowledge of solid state solubility will
facilitate in determining percent drug loading while design and development of solid
dispersion formulation for solubility enhancement.
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CHAPTER 4
THERMAL AND CHEMICAL CHARACTERIZATION OF SOLID DISPERSIONS
PREPARED WITH EUDRAGIT® E PO AND IBUPROFEN
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Introduction
Solubility enhancement of poorly water soluble BCS Class II and IV drugs has been one
of the most important challenges as about 40-70% of new drug molecules are poorly
water soluble(3).Solid dispersions offer the ability to freeze a drug molecule in its most
high energy amorphous form increasing the apparent solubility (18, 46, 71, 92).
Methods for manufacturing solid dispersions include freeze drying, spray drying, solvent
film casting, self-emulsifying lipid formulations and hot melt extrusion (HME). Formation
of a solid facilitates stabilization of the API in its high energy amorphous state for an
extended period of time. A lot of focus is given to characterization of physical form of the
drug in solid dispersions. In some instances however, amorphization of the drug may
not be the sole contributing factor for solubility enhancement. Systems containing ionic
complex of a drug with an excipient offer the ability to further increase the apparent
solubility of a poorly water soluble drug (93, 94).
Solubility of a drug in a polymer is usually very low therefore it is difficult to meet the
conventional dose requirements with solid dispersion formulations. For this reason,
most solid dispersions potentially are developed as supersaturated systems. In some
cases additional stabilizers and solubilizers are necessary to assist in solubility
enhancement. Selection of the appropriate polymeric excipient is critical to have the
highest concentration of drug solubilized. Strong drug-polymer interactions are
favorable due to their ability to produce stable, higher drug load solid dispersions.
Strategic selection of excipients to form ionic interactions offers the ability increase the
apparent solubility of the drug. In the previous chapter polymers of varying chemistries
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were investigated for compatibility with the model drug ibuprofen. In this chapter further
thermal and chemical characterization of binary solid dispersions prepared using
Ibuprofen and Eudragit® E PO is performed.
For formulation optimization using HME, it is essential to understand the important
physicochemical properties such as the Glass Transition (Tg), melt viscosity, solid-state
saturation solubility and interactions between the drug and the excipients incorporated.
A phase diagram describing the effect of temperature and the ratio of ibuprofen on the
physical state of the drug is investigated in this study. Since maintaining stable
amorphous state of the drug via solid dispersion formulation is critical for solubility
enhancement knowledge of the phase diagram will provide vital information required for
developing stable solid dispersions.
For an immediate release formulation, increased solubility of a drug in the gastric pH is
advantageous as the dissolution process starts as soon as the drug is orally
administered. This also ensures that the drug is in the solubilized form and ready for
absorption on entering the intestine (91). Eudragit® E PO is a good solvent for many
classes of drug molecules mainly anionic and neutral drug. Due to the low Tg of this
polymer processing using solid dispersion manufacturing techniques like HME and
spray drying can get challenging when working with a drug molecule with a low Tg. For
this reason, thorough understanding of thermal and chemical properties of this excipient
is essential in order to determine experimental conditions within which stable processing
can be achieved. In detail study on the effect of processing parameters on quality of the
final product is presented in chapter 5.
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In the present study, thermal and chemical characterization of ibuprofen and Eudragit®
E PO binary mixtures have been performed using thermal and spectroscopic methods.
Eudragit® E PO, is an amorphous polymer with a Tg at about 45°C is insoluble in
aqueous systems above pH 5.5 making it an excellent carrier for taste masking bitter
drugs. Ibuprofen a low melting (75-77°C), anionic drug is selected as a model drug as
model drug. Ionic interactions between Eudragit® E PO and acidic drugs have been
investigated by solubility measurement and FTIR spectroscopy.
Materials
Ibuprofen was generously donated by Albermarle. Eudragit® EPO was obtained from
Evonik (Piscataway, NJ). Chloroacetic acid, acetonitrile and ammonium hydroxide were
purchased from fisher Scientific (Pittsburgh, PA)
Methods
Phase Diagram
Phase diagram was calculated based on the melting point depression method and the
Flory-Huggins theory(95). According to the Flory-Huggins theory, a temperature
composition phase diagram can be constructed for a given drug-polymer system if the
Flory chi parameter is known for a given temperature range. Melting point depression
method has been used previously to predict the value of ! by Marsac et al based on the
equation 4.1.
!
!!

!

!

!

! − ! ! ! = ! − !" ! !"!! + ! ! − !
!

! − ! + !! ! − !
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!

( 4.1)

!
Where T! is the melting point of the drug polymer mixture, T!
is the melting point of the

pure drug, ! is the volume fraction of the drug, m is a constant derived from the ratio of
the volume of a polymer to that of the drug molecule and ! is the Flory- Huggins
interaction parameter(27, 53). It was recently noted that the Flori-Huggins interaction
parameter is temperature dependent(96, 97) .A relationship between ! and temperature
can be expressed based on the equation 4.2.
!

! = ! +!!

(4.2)

Where A is a constant from non-combinatorial entropic contribution to ! and B/T is a
constant coming from the enthalpic contribution(98).
The free energy of mixing can be written in terms of the Flory-Huggins parameter as
shown in equation 4.3
!" = !"! !"#! + !

!!!
!

!!" ! − ! + !!!!(! − !)

(4.3)

The crystalline phase boundary is calculated using predicted values of Tm based on the
equations4.1 and 4.2. In order to calculate the spinoidal curve for phase separation, Ts
is calculated from the second derivative of equation 4.3 equated to zero as shown in
equation 4.4.
!

!

!

+ ! (!!!) − !" = !
!

( 4.4)
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Melt Extrusion
Powder blends of Ibuprofen with Eudragit® E PO were prepared by mixing accurately
weighed powder components using a Turbula T2F shaker mixer (Glen Mills Inc.Clifton,
NJ) for 10 min. Melt extrusion was performed in 40 gm batch sizes using a co-rotating
twin screw extruder (Leistritz Nano 16, American Leistritz Corporation, Somerville, NJ).
Screw rotation speed (150 rpm) and feed rate (5cc/min) using the bottom plunger feeder
was maintained constant for the entire set of experiment. Due to the plasticizing effect
of ibuprofen, extrusion temperature was adjusted based on the Tg of the mixture and
ranged from 80 to 140°C. The resulting extrudates were stored at room temperature in
air tight containers until further analysis.
Thermal Analysis
Differential Scanning Calorimetric (DSC) analysis was performed on the drug polymer
solid dispersions using a Pyris 6 DSC (PerkinElmer, Waltham, MI). 8 – 10 mg of the
milled extrudate was weighed, crimped in an aluminum pan and subjected to a heatcool-heat cycle.
Measurement of glass transition: Samples were heated from 0 to 100°C at the rate of
10°C/min, cooled to -50°C at 40°C/min and reheated up to 120°C at heating rate of
10°C/min under nitrogen purge of 20 ml/min. The first heating eliminated the deviations
caused from the thermal history and moisture whereas the second heating facilitated in
the determination of Tg. DSC scans for the pure ibuprofen and Eudragit® E PO was
measured as controls.
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Melting point depression measurement: Binary mixtures of ibuprofen and Eudragit®
E PO containing 65, 70, 75, 80, 85, 90 and 95% ibuprofen were dissolved in 5mL
ethanol and stirred until a homogenous solution is obtained. This solution was poured
into a petri dish (35mm) and allowed to dry for 3 days under a hood. The resulting films
were analyzed in a DSC first by cooling to -50°C, heating from -50°C to 40°C at
10°C/min followed by heating from 40°C to 90°C at 1°C/min to measure the melting
point. The melting point was calculated at the falling edge of the melting endotherm.
Optical Microscropy
Optical analysis were performed on the extruded samples using an Olympus BX51
microscope (Center Valley, PA) coupled with polarized filters to evaluate the drug’s
physical state. A 1:1 physical mixture of ibuprofen and Eudragit® E PO was observed
under a microscope for 12 days.The melt extruded samples were examined for
recrystallized ibuprofen periodically over a span of 1 year.
XRPD
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Corporation,Billerica,

(XRD)

was

MA,

USA).
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using
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assisted
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(Bruker
physically

determining the presence of crystalline phase. This analysis verified the results of the
DSC measurements as well as phase diagram prediction.
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FTIR
The ATR-FTIR was used to identify the ionic interactions between the drug and the
polymer. The IR spectra of the samples were collected by placing the samples in
powder or film form on a single-reflection diamond ATR (Attenuated Total Reflectance)
accessory. 32 scans were obtained for each sample at the resolution of 2 cm-1.
Solubility Measurement
Increasing amount of Eudragit® E PO was added to super saturated solutions of
ibuprofen in 10 mL 0.1N HCl and allowed to equilibrate overnight. Resulting solutions
were filtered and the supernatant solution was analyzed using a HPLC system equipped
with a photodiode array detector at 254nm (Waters Corporation, Milford, MA) along with
a C18 column (Waters Xbridge, 3.5 micron, 4.6x 150 mm). A mobile phase consisting of
1% chloroacetic acid buffer solution adjusted to pH 3.0 with ammonium hydroxide and
acetonitrile in the ratio 20:80 was used at a flow rate of 0.8 mL/min. All the standards
and assay samples were prepared in acetonitrile. To test the effect of change in pH on
the saturation solubility of ibuprofen supersaturated solutions of ibuprofen were
prepared using pH 4.5 and 6.8 buffer solutions. pH values for all the solubility samples
along with 300mg and 500mg Eudragit® E PO dissolved in 10 mL 0.1N HCl as controls
were recorded.
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Results and Discussion
1. Thermal Characterization: Phase Diagram
The DSC thermograms measured for various ratios of ibuprofen and Eudragit® E PO
are shown in Figure 4.1. The solvent casting may increase the amount of amorphous
drug due to the presence of polymer chains resulting in melting point depression. This
also provides an evidence of intimate mixing between the drug and the polymer. The
crystalline ibuprofen shows a sharp melting peak at 78.08°C and this further decreases
as the concentration of Eudragit® E PO in the system increase. The melting point
depression data was used to calculate the Flory Chi parameter for the ibuprofen –
Eudragit® E PO system based on equation 4.1. Table 4.1 shows the values of the
physical properties that were used in calculation of the constant m.
Table 4.1: Molecular Weight and Density of Ibuprofen and Eudragit® E PO
Molecular Weight

Density (gm/ml)

Ibuprofen

206.28

1.03

Eudragit EPO

47000

0.811
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Figure 4.1: DSC thermograms of Ibuprofen and solvent casted solid dispersions of
Ibuprofen and Eudragit® E PO obtained at a scanning rate of 1°C/min

Figure 4.2: Flory-Huggins interaction plot based on equation 4.1
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A Flory-Huggins interaction plot based on the equation 4.1 is shown in Figure 4.2. The
slope of the straight line is the value of the Flory Chi interaction parameter and for the
current study the calculated Chi is -1.52. Negative Chi values are associated with higher
degrees of miscibility therefore the components are predicted to have high compatibility
resulting in stable solid dispersions. Measurements of Flory Chi parameter based on the
melting point depression data has been performed for similar pharmaceutical systems
(27, 28)

Figure 4.3: A plot showing the relationship between the interaction parameter and
temperature.
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The melting point data can be used to extrapolate the value of Chi at different
temperatures using equation 4.1. There exists an inverse relationship between Flory Chi
and Temperature as shown in equation 4.2. The predicted interaction parameter values
are plotted against 1/T to get an equation of the straight line based on equation 4.2, !
=5794/T-18.61. The values of A and B are further used to predict the phase boundaries.
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Figure 4.4: A plot showing Gibbs free energy changes with respect to temperature for
Ibuprofen-Eudragit® E PO system
The phase diagram predictions are based on the Gibbs Free energy calculated using
the equation 4. 3. Phase separation is dependent on the difference of the Gibbs free
energy between the mixed and unmixed states which is also referred to as ΔGmix(74). A
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plot of ΔG/RT against the ratio of ibuprofen is presented in Figure 4.4. It can be seen
that at temperatures above 25°C the ΔG is negative across all ratios of ibuprofen
indicating that at this temperature the system is miscible at all concentrations. At 20°C
the ΔG starts getting positive at an ibuprofen concentration of 75%w/w whereas at 10°C
the ΔG starts becoming positive at a concentration of 25%w/w. Overall, miscibility
reduces as the temperature drops.
The relationship between the Gibbs free energy, temperature and volume fraction of the
drug can be used to calculate the temperature at which phase change occurs for each
volume fraction of the drug. The spinoidal curve is calculated by equating the second
derivative of the Gibbs free energy to zero as presented in equation 4.4. This is the
boundary that outlines the miscibility limits of the two systems where the drug is present
in a metastable state. In this region, the system may be sensitive to fluctuations in the
levels of temperature or composition and may cause nucleation and recrystallization
with larger fluctuations. The predicted melting points outline the region between
crystalline and amorphous ibuprofen.
Tg for the mixtures were measured experimentally using DSC measurements. The first
heating eliminated prior thermal history of the material as well as the moisture present in
the sample whereas the second heating cycle allowed determination of Tg. For samples
in which ibuprofen exists in two phases (crystalline and amorphous), a melting event
around 70°C can be detected in the first heating cycle. A change in the Tg can be
witnessed in the DSC thermograms as seen in Figure 4.5.
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Figure 4.5: Tg determination for binary mixtures of Ibuprofen and Eudragit® E PO

Figure 4.6: Predicted phase diagram for Ibuprofen and Eudragit® E PO system
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A phase diagram is a graphical representation of phase boundaries in relation to the
temperature and composition. A predicted phase diagram for ibuprofen –Eudragit® E
PO system is presented in Figure 4.6. Based on the phase diagram, it can be seen that
the mixture of two components exists in a miscible state at room temperature.
Room temperature Miscibility Study
To further explore the fact that that the Tg of high ibuprofen containing (<50%) samples
is well below the room temperature (Figure 4.7) a miscibility study was conducted. A 1:1
mixture of powder Eudragit® E PO and Ibuprofen was observed under an optical
microscope (100X) for a period of 12 days. Particles of Eudragit® E PO coated the
ibuprofen crystals as seen on day 1 due to their significantly lower particle size and
strong adhesive forces. The strong interactions between the two components slowly
start dissolution process and the size of the ibuprofen crystal appears to be reduced as
the days progress as seen in Figure 4.7 (a – h). Towards the end of 12 days the distinct
shape of ibuprofen crystal disappeared indicating that the ibuprofen was most likely
converted to its amorphous form due to solubilization in the polymer solvent. This is
further confirmed by observation of crystals under polarized light. The outlines for
ibuprofen crystals are clearly visible on day 5 whereas the day 10 image shows no
reflectance under polarized light indicating absence of crystals as seen in Figure 4.5.
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Figure 4.7: Room Temperature Miscibility

(a) Day 1:

(b) Day 2

(c) Day 5

(d) Day 6

(e) Day 7

(f) Day 8
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(g) Day 9

(h) Day 12

Under polarized light (i) Day 5

(j) Day 10

2. Chemical Characterization
The mutual miscibility of ibuprofen and Eudragit® E PO can be attributed to their
chemical structure. Chemical characterization was carried out to test for presence of
intermolecular interactions.
FTIR
The room temperature miscibility study visibly shows the solubilization process between
the two components. FTIR scans on the melt extruded samples further verify the
formation of molecular interactions. The FTIR spectra show a broad peak at 1567cm-1
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(absent in the physical mixture) which may be associated with the bending N-H bond
vibrations. This could be an indication of interaction between the carboxylic acid group
of the ibuprofen molecule and the dimethylaminoethyl group of the EUDRAGIT® E PO.
Schematic representation of complex formation is presented in Figure 4.8.

Figure 4.8: FTIR spectra of Ibuprofen-EUDRAGIT® E PO samples (--) Ibuprofen, (--),
Eudragit® E PO, (--) Physical Mixture, and (--) Melt Extrudates with 50% Ibuprofen
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Figure 4.9: Schematic of Ionic Interactions
XRPD
The XRD scans are essential to determine the physical state of the drug. In this study
XRD analysis was performed to verify the results obtained from DSC. It can be seen in
Figure 4.10 that the crystalline ibuprofen shows distinctive peaks at 6, 16.5, 18, 20 and
22.5 degrees owing to the specific arrangement of the atoms. Melt extrudates with 30,
50 and 70% ibuprofen have been analyzed to detect the presence of crystalline phase.
Crystalline phase could not be detected in the extrudates with 30 and 50% ibuprofen.
However, the melt extruded formulation with 70% ibuprofen shows the same
characteristic peaks as that of the pure ibuprofen indicating presence of crystalline
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phase. These findings further support the results of the thermal and microscopic
assessment.
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Figure 4.10: XRPD scans of Ibuprofen and Eudragit® E PO melt extrudates
Increase in apparent solubility
Ibuprofen has a pH dependent solubility with a pKa=4.85 and is poorly soluble at acidic
gastric pH. For an immediate release formulation it is advantageous if the drug
dissolution process is triggered as soon as the formulation is administered orally so that
the drug is ready to be absorbed upon entering the intestine(91, 99). Solubility studies
have shown that the saturation solubility of ibuprofen at pH 1.2 increases with increase
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in the concentration of the cationic polymer (Figure 4.11). This increase could be due to
the

molecular

interactions

between

the

carboxylic

group

of

ibuprofen

and

dimethylaminoethyl group of the EUDRAGIT® E PO. This was further tested by
measuring the change in pH of the solubility measurement samples with the addition of
the cationic polymer. The pH of the saturated solution of ibuprofen with the maximum
concentration of (500mg in 10 ml) of Eudragit® E PO tested was 4.5 whereas that of a
control sample with same amount of Eudragit® E PO was about 6.6. The saturation
solubilities obtained at pH 4.5 and 6.8 were 0.17 and 2.19 mg/mL respectively. This
suggests that the increase in solubility was not due to increase in the pH level.

Saturation solubility of Ibuprofen Vs Eudragit® E PO
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Figure 4.11 Saturation solubility of Ibuprofen Vs Eudragit® E PO amount
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Figure 4.12 Saturation solubility of Ibuprofen

Figure 4.13: Melt Extruded samples (70% Ibuprofen loading) at (a) 30 days (b) 365
days
Stability
Melt extruded samples stored at room temperature were observed under polarized light
for a period of one year. Samples with 40 and 55% ibuprofen show no signs of
recrystallization and were stable at room temperature over the study period. Ibuprofen
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begins to recrystallize from the melt extruded samples with 70% within a week of
manufacturing. Figure 4.13 shows microscopic pictures of ibuprofen crystals as seen
under a polarized light microscope captured at 30 and 365 days. The nucleation
process started in a week after manufacturing and the crystals were observed to grow in
size with aging.
Conclusion
In this study, solid solutions of ibuprofen and Eudragit® E PO are characterized using
thermal and microscopic tools. Room temperature miscibility studies provide visible
evidence of strong affinity between the two components. The strong mutual affinity is an
additive effect attributed to two components viz. the presence of ionic groups together
with low Tg of the mixture. Solid solutions prepared by melt extrusion with ibuprofen
loading 40 and 55% are physically stable at the end of 365 days whereas formulations
with a drug loading of 70% tend to recrystallize. Stable solid dispersions with high drug
loading can be achieved by selecting excipients with favorable functional groups. The
saturation solubility of ibuprofen in acidic media increased up to 12 fold which could be
attributed to formation of ionic interactions. This is translated in in vitro dissolution
studies where the ibuprofen release is increased 3 fold as seen in Chapter 3 of this
document on page 29. This is advantageous for immediate release formulations since
the dissolution process starts as soon as the drug is orally administered.
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CHAPTER 5
A QUALITY BY DESIGN (QBD) STUDY ON PREPARATION OF SOLID
DISPERSIONS USING MELT EXTRUSION PROCESS
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Introduction
Over the past two decades Hot Melt Extrusion (HME) has steadily gained interest in the
pharmaceutical industry owing to the versatile nature of this process(14). Depending on
the type and combination of excipient selected, HME offers the ability to develop
formulations with wide applications ranging from immediate release(29), taste
masking(31), controlled release(30), enteric release(32), pulsatile release as well as
sterile biological inserts(33). However, solubility enhancement via formation of
amorphous solid dispersions (SD) remains to be the most widely explored application
for HME as 40 to 70 % of New Chemical Entities (NCEs) are poorly water soluble(3).
During SD formation, the drug molecule is entrapped in its most soluble high-energy
amorphous form by entrapment within the polymeric matrix(71).
HME offers the ability to combine several individual unit steps such as feeding, meltmixing along with numerous downstream processing options like pelletization, granules,
milled particles, films and custom shapes using injection molding in a continuous
sequential manner. In spite of the high interest and extensive research only a handful of
products available on the market are prepared using this technology. This could be due
to (i) perceived high startup costs (ii) challenges involved in selection of appropriate
excipients and subsequent prediction of long term stability, as well as (iii) insufficient
understanding of the critical formulation and process parameters and their implications
on scale up.
Quality by Design (QbD) is strategic product development approach initiated by the
Food and Drug Administration (FDA) that considers both, formulation and process
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related factors that affect the quality attributes of the final product(57). Pharmaceutical
QbD requires a thorough understanding of the product and the process along with the
knowledge of the relationship between the Critical Quality Attributes (CQAs) and the
clinical performance of the product. The effect of individual process parameters on the
final product’s CQAs is studied with the help of statistical Design of Experiments (DoE)
through which an operational Design Space (DS) is established. As a result of this, a
range of variability is defined for each variable under which the CQAs remain within the
pre-established limits. Thus a controlled DS is generated for the process. Although
adapting QbD methodology initially could be cumbersome it will eventually mean less
paperwork and resources when a change needs to be introduced in the manufacturing
process. It will also reduce overall waste produced during manufacturing as well as
allow efficient globalization for companies with manufacturing sites across the
world(58),(59).
The current QbD methodology involves four major stages: 1. Establishing Quality Target
Product Profiles (QTPP) and Critical Quality Attributes (CQAs); 2. Risk Assessment; 3.
DoE-based screening and hence establishing a Design Space (DS); and 4. Control
Strategy and continuous improvement(57). This pharmaceutical QbD approach has
been applied to various manufacturing processes such as tablet compression,(59)
accelerated

stability

liposomes,(66)

spray

testing,(100)
drying,(62,

solubility
63)

enhancement

fluid

bed

and

dissolution,(101)

granulation(60)

and

gel

manufacturing(69). However this current study focuses on application of QbD
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framework to a pharmaceutical melt extrusion process, which to date has not been
reported.
This present body of work is a case study for developing taste masked granules of
ibuprofen using Eudragit® E PO using a step-by-step QbD approach. Eudragit® E PO is
a cationic polymer that is insoluble in water above pH 5.5. This property makes it an
excellent excipient for taste masking of bitter drugs as it is insoluble at the normal pH of
human saliva, which ranges from 6.5 to 7.4. Ibuprofen is a non-steroidal antiinflammatory agent belonging to BCS (Biological Classification System) Class II (poorly
soluble and highly permeable)(102). It is an anionic drug with pH dependent solubility
and readily ionizes at the pH of human saliva (6.5 to 7.4) making it an excellent model
drug to test the taste masking efficiency of a formulation.
A thorough risk analysis study using both qualitative and quantitative methods for
preparation of granules using melt extrusion was performed. Fishbone diagram and
Failure Mode Effect Analysis (FMEA) were the tools used for qualitative risk analysis.
For further quantitative investigation a 6 factor 2 level Plackett-Burman screening
design was formulated to examine the main effects. In order to study potential
interactions four factors within the Plackett-Burman study were selected for an
expanded Response Surface Design (RSD). Utilizing these data, a DS for preparation
of granules using melt extrusion was developed. The steps involved in this QbD study
are summarized in Figure 5.1.
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Rate, blending type,
Level of processing
aid, Level of
Eudragit® E PO
Assay, Dissolution,
Torque, Glass
Transition and
Physical Appearance

Selection of Critical
Parameters
Screening Design
Optimization Design

Level of Drug. Extrusion
temperature, Level of
processing aid, Level of
Eudragit® E PO

Critical Quality Attributes
Data Analysis and Design
Space Generation

Figure 5.1 QbD steps applied to the melt extrusion process
Materials
Ibuprofen was generously donated by Albemarle Corporation (Orangeburg, South
Carolina). Eudragit® E PO was obtained from Evonik Corporation (Piscataway, NJ).
PVP 25 was purchased from Sigma-Aldrich (St. Louis, MO). HPLC grade acetonitrile,
chloroacetic acid, ammonium hydroxide, potassium phosphate and sodium hydroxide
were purchased from VWR chemical supplies (Radnor, PA).
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Methods:
Risk Assessment (RA)
Risk assessment facilitates strategic short listing and ranking of select significant
parameters from hundreds of potentially critical parameters. The RA study began with
devising and enlisting all of the factors that contribute to the quality of the final product
in the form of a cause and effect or an Ishikawa diagram.(70) Based on the parameters
highlighted by the Ishikawa diagram, a table for Failure Mode Effect Analysis (FMEA)
was developed outlining all of the process steps from powder blending to extrusion. A
team of 5 multidisciplinary experts graded each failure mode on a scale of 1 to 5 with
regards to the severity (S), occurrence (O) and detectability (D) of that particular event.
Finally a product of all three values (S*O*D) was computed to yield the Risk Priority
Number (RPN).
Experimental Design
Plackett-Burman design has been shown to be efficient for studying the main effects
between the critical factors with minimum experimental runs(103). Based on the risk
assessment results, the shortlisted factors were further analyzed using a PlackettBurman screening design consisting of 6 factors studied at two levels along with 2
center points resulting in a total of 14 extrusion experiments. The high and low level
values of these factors were based on available literature (31, 104) and prior extrusion
experience with Eudragit® E PO (data not shown).
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Based on the results of the Plackett-Burman Design, four factors (Level of Drug: X1,
Extrusion temperature: X3, Level of processing aid: X6 and level of Eudragit® E PO:
X7) which had the highest impact on the CQAs, were selected for a custom designed
Response Surface Design (RSM) with 16 additional runs. The RSM design allowed
investigation of potential interactions between the independent variables. A list of the
factors studied (independent variables) along with their levels and the measured
responses (dependent variables) is presented in Table 5.1. The level of each study
variable in the experimental design can be seen in Table 5.2.
Statistical Analysis
Plackett-Burman design, augmentation of design to a RSM and all statistical
calculations were performed using JMP® Version 9 (SAS Institute Inc, Cary, NC, USA)
and Modde 10.0 (Design of Experiment software by Umetrix). Responses were
analyzed using analysis of variance (ANOVA) and Partial Least Square (PLS).
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Table 5.1: Experimental domain in Plackett-Burman Design
Variable

Low Level

High Level

X1

Level of Drug (%w/w)

30

70

X2

Screw Speed (rpm)

75

150

X3

Extrusion temperature (°C)

80

140

X4

Feed Rate (cc/min)

4

6

X5

Premixing

0

10

X6

Processing Aid (%w/w)

0

20

X7

Level of Eudragit® E PO

10

70

Y1

Torque

Y2

Glass Transition (°C)

Y3

Assay (%w/w)

Y4

Drug Released in 0.5 hr

Y5

Phase Change
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Table 5.2: Experimental Design (PB-1 to PB-14: Plackett-Burman design, O-15 to O-30:
Optimization design)
Screw

Extrusion

Eudragit

Speed

Temperature

Ibuprofen
Batch

Feed Rate

(%w/w)

Processing
Mixing

(cc/min)
(rpm)

(°C)

E PO
Aid (%w/w)
(%w/w)

PB-1

0.3

75

100

6

0

0.1

0.6

PB-2

0.3

75

120

4

0

0

0.7

PB-3

0.3

150

120

4

10

0

0.7

PB-4

0.3

150

100

4

10

0.1

0.6

PB-5

0.3

150

100

6

10

0

0.7

PB-6

0.3

150

120

6

0

0.1

0.6

PB-7

0.5

75

100

4

10

0.1

0.4

PB-8

0.5

75

100

6

0

0

0.5

PB-9

0.5

75

120

6

10

0.1

0.4

PB-10

0.5

150

100

4

0

0

0.5

PB-11

0.5

150

120

4

0

0.1

0.4

PB-12

0.5

150

120

6

10

0

0.5

PB-13

0.4

112.5

110

5

5

0.05

0.55

PB14

0.4

112.5

110

5

5

0.05

0.55

O-15

0.3

112.5

80

5

0

0

0.7

O-16

0.5

112.5

140

5

0

0

0.5

O-17

0.3

112.5

80

5

0

0.2

0.5

O-18

0.7

112.5

110

5

0

0.2

0.1

O-19

0.3

112.5

140

5

0

0.2

0.5

O-20

0.7

112.5

140

5

0

0.1

0.2
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®

O-21

0.7

112.5

80

5

0

0.1

0.2

O-22

0.7

112.5

110

5

0

0

0.3

O-23

0.3

112.5

110

4

0

0

0.7

O-24

0.3

150

110

5

0

0

0.7

O-25

0.7

112.5

140

5

0

0.2

0.1

O-26

0.3

112.5

110

5

0

0.2

0.5

O-27

0.3

112.5

110

6

0

0

0.7

O-28

0.5

150

110

5

0

0.2

0.3

O-29

0.7

112.5

80

5

0

0.2

0.1

O-30

0.3

75

110

5

0

0

0.7

Melt Extrusion
Dry powder ingredients were sieved through a USP# 35 sieve to remove agglomerates
and accurately weighed in a plastic bottle. The powder blends were subjected to either
mixing for 10 min in a Turbula T2F shaker mixer (Glen Mills Inc. Clifton, NJ) or hand
mixed. The blends were then extruded using a 16 mm co-rotating twin screw extruder
(Leistritz Corporation, Allendale, NJ) equipped with a bottom feeding assembly and
fitted with a 4mm round die. The heating zone closest to the feeding zone was
maintained at 70°C throughout the course of this study whereas heating zones 2, 3 and
4 were maintained at a temperature stated in the study design. The screw speed (rpm),
feed rate (cc/min) and the concentration of anti-tacking agent were set up according to
the study design as shown in Table 5.2. The prepared extrudates were stored in airtight
containers until further processing.
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Extrudate Characterization
Ibuprofen Content
All melt extruded samples were assayed for ibuprofen content using an Agilent 1100
series HPLC system (Agilent Technologies Inc, Santa Clara, CA, USA) attached to a
variable wavelength detector at 254 nm along with a C18 column (Phenomenex Luna
5µ). A mobile phase consisting of 1% chloroacetic acid buffer solution adjusted to pH
3.0 with ammonium hydroxide and acetonitrile in the ratio 20:80 was used at a flow rate
of 0.8 mL/min. All of the standards and assay samples were prepared in methanol.
Dissolution
Milled extrudate samples equivalent to 200mg of ibuprofen was filled in a size 00 clear
gelatin capsule. Dissolution on the filled capsules was performed (n=3) using USP
apparatus 2 with a Varian VK 750 D dissolution apparatus at 37ºC at a paddle speed of
50 rpm in biphasic media consisting of pH 1.2 for the initial 60 min. This method was
followed by utilizing pH 6.8 (simulation of GI tract conditions) until complete ibuprofen
release was attained. Dissolution samples were filtered and analyzed using the abovedescribed HPLC method. A control sample, where 200mg of pure drug was placed in a
size 00 clear capsule was used for comparison.
Measurement of Tg
Differential scanning calorimetric analysis was performed on the milled samples using a
Pyris 6 DSC (PerkinElmer, Waltham, MI). 8–10 mg of the milled extrudate was weighed,
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crimped in an aluminum pan and subjected to a heat-cool-heat cycle. The first heating
eliminated the thermal history and moisture whereas the second heating facilitated in
the determination of Tg. Samples were heated from -30 to 120°C at the rate of
20°C/min, cooled to -30 °C at 40°C/min and reheated to 120°C at 20°C/min under
nitrogen purge of 20 mL/min. The Tg was calculated from the resulting thermograms
using the Pyris 6 software.
Results and Discussion
The document Q8 published by the International Conference on Harmonization (ICH)
illustrates and defines the steps involved in a pharmaceutical QbD process(57). The
steps followed in this study are outlined in
The first step for a Quality by Design study is to establish a vision for the end product by
defining the Quality Target Product Profile (QTPP) for the final product. (57, 58) QTPP
is a grouping of several chemical, physical, biological, microbiological or esthetic
attributes of the product that are essential to ensure the quality and performance of the
drug product. Table 5.3 lists the established QTPP for the melt extrudates manufactured
in this study, which include the ibuprofen content, in vitro dissolution and physical
appearance. These parameters provided as a starting point for establishing the ranges
of CQAs that serve as a guide throughout the product development phase. The focus in
this QbD study was to understand the relationship between the experimental
parameters and formulation composition (independent variables) with the quality
attributes (responses) that are involved in the melt extrusion process.
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Table 5.3: Quality Target Product Profile
Product attribute

Target

Assay

> 95% w/w

Dissolution at pH 1.2

> 60% ibuprofen released in 60 minutes

Dissolution at pH 6.8

100% of ibuprofen released within 30 minutes

Physical appearance

Clear, non-tacky

Risk Assessment
From amongst hundreds of factors that potentially affect the melt extrusion product
development, narrowing down to a few most critical parameters for experimental
evaluation can be very challenging. A systematic risk assessment study not only
outlines several factors affecting the process but also prioritizes them based on the
severity of their impact on the product. In this work, a two-stage risk assessment study
is conducted to strategically narrow down the most influential parameters. In the first
step a cause and effect (or Ishikawa diagram) has been utilized to outline a multitude of
factors contributing from categories such as machine, manpower, materials, methods,
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measurement and environment(70). The Ishikawa diagram outlining several formulation
and process parameters affecting the melt extrusion process is illustrated in Figure 5.2.
All of the resulting factors were then treated as failure modes in a FMEA table, which
lists the severity, occurrence and predictability for each factor and prioritizes all of the
risks in the form of a risk priority number (RPN). FMEA is a risk assessment tool that
focuses on minimizing the potential failures before they occur and assists in developing
a step by step approach to reduce the future risk of failure by making appropriate
changes to the process(105). Table 5.4 lists several failure modes with respect to the
current study along with their effects, causes and controls. These failure modes were
graded on a scale of 1 to 5 by five experts in this field of study. The final impact of a
failure mode is decided based on its RPN score calculated as an average score from all
five evaluations. Drug degradation, melt viscosity, tackiness, flow characteristics and
drug recrystallization were the failure modes that received the highest RPN scores.
These are process and formulation variables that can be tested within a specified range.
These attributes were translated into measurable responses quantified as % Ibuprofen
content, Tg of the extrudate, in process torque and % ibuprofen released at 30 min.
Extrudates were examined under a microscope to detect crystallization and qualitative
phase change.
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Extrusion

Temperature
Weighing
Type of Blender
Screw Configuration
Blend Uniformity
Screw Speed
End Point
Screw Dimension
Stability of Powder Blend
Feed Rate
Raw Materials
Torque
Die Dimension
API solubility/
Excipients
API
Tg of Mixture
Personnel
Training
Temperature /
Humidity

Plant Factors

Characterization
Dissolution/
Solubility
Enhancement
Stability/
Reproducibility
Crystallanity
(DSC/XRPD/
Microscopy)

Batch Volume

Miling

Feedrate
Flowability
Injection of Plasticizer/
Multiple Feeder

Extrudated
Particles

Sieving
Shaping
Capsule Filling

Feeding

Figure 5.2: Ishikawa diagram for preparation of extruded particles

Downstream
Processing
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Blending

Process
step
Formulation

Blending

Feeding

Failure Mode

Failure effects

Controls

S

O

D

RPN

Actions

Compromised
dissolution

Causes of
failure mode
Supersaturati
on

Drug polymer
ratio

Optimization of
drug-polymer ratio

5

3.3

1.3

23.3

Phase
Change

Recrystallizatio
n

Supersaturati
on

Optimization of
drug-polymer ratio

4.6

3

1.6

23

Chemical
Interactions

Tackniess

Lowering of
Tg

4.3

3

1.3

16

Content
uniformity

Inappropriate
blending time

2

3

3.8

28.3

Flow
Characteritics

Uneven
distribution of
drug in the
drug-polymer
mixture
Improper flow,
feeder jam

Lower drug
loading, revise
formulation
NIR/HPLC

Optimization
of drugpolymer ratio
Optimization
of drugpolymer ratio
Lower drug
loading, revise
formulation
Optimize
blending
conditions

3.8

3

4.8

53.3

Optimize
glidant
concentration
and feed rate

Liquid
Injection

Non-uniform
feeding

Pump
malfunction

Particle Size,
Angle of Repose,
bulk density, tap
density, Addition of
glidant
Flow rate
optimization

5

1.5

3.5

25

Feeder Jam

Inefficient
feeder
Functioning,
Bridging or
Arching

Poor flowing
material

Feeder speed and
conveying screw
optimization

3.8

2

3.5

33

Calibrate
pump, operate
within
calibrated
range
Add glidant,
change feeder
screws

Inadequate
understanding
of particle
properties
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Table 5.4: Failure Mode Effect Analysis for Melt Extrusion Process

Drug
Degradation

Polymer
Degradation

Drug content
loss due to
degradation ,
low assay
content
Discoloration/
charring, drug
content loss
due to
impurities

Too high
temperature,
Drug/Polymer
interactions

lower extrusion
temperature and
monitor color
change

5

3

4.3

62.5

Reduce
extrusion
temperature

Too high
temperature,
Drug/Polymer
interactions,
Too high shear
forces
Temperature
lower than
necessary, low
plasticizer

lower extrusion
temperature and
monitor color
change

5

3

2.3

33.8

Reduce
extrusion
temperature

Monitor torgue
and viscosity
values

4.8

3

4.3

60.5

Increase
temperature/
Lower screw
speed,
increase
plasticizer
concentration
Decrease
temperature/
Decrease
plasticizer
concentration
Revise screw
design

High melt
viscosity

Extruder
shutdown due
to overtorgue

Low melt
viscosity

Material is very
liquid, too sticky
for conveyor
belt cooling

High extrusion
temperature

Lower extrusion
temperature

3.3

2.5

4

28

Extrudate
Content
Uniformity

Uneven mixing
of drug in the
extrusion batch

Screw
configuration,
Length of the
cylinder

PAT tools
(NIR/RAMAN)

4.3

3

3.3

41.5
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Extrusion

High back
pressure
Cooling/
Conveying

Uneven
diameter of
extrudate

Milling

Particle size
distribution
Tackiness

Storage
conditions

Recrystallizati
on

Dissolution
characteristics,
visual
appearance,
Physical
Stability,
Cooling Rate
Blocking of the
die, instrument
shutdown
Uneven
thickness, a
strand that is
not continuous
Wide particle
size distribution
Granules stick
to each other
during storage
forming lumps
Recrystallizatio
n affecting the
drug dissolution

High drug load,
extrusion
temperature,
residence time,
polymer
characteristics

PAT tools
(RAMAN)

4.3

3.5

3

36.5

Revise
formulation

die diameter,
die
temperature
Feeder speed,
conveyor belt
speed

PAT tools:
(Pressure
sensor)
Belt speed

3.3

1.8

4.3

24

1.5

2.8

3.8

14.5

Blade speed,
sieve number
Low glass
transition
temperature of
the drug
Moisture and
storage
temperature

Optimize speed
and sieve size
Store at a lower
temperature,
add anti-tacking
agent
None

1.5

3.3

3.8

20.5

3.8

3

4.5

52.3

5

3.5

3.5

60

Reduce screw
speed, increase
die diameter
Adjust belt
speed, keep the
feeder speed
uniform
Optimize speed
and sieve size
Increase
concentration of
antitacking
agent
Monitor storage
conditions,
Store in a
refrigeration
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Crystallization
of API

Statistical Design and Analysis
Table 5.5 shows the response values for all the experiments. The results of the
screening study showed that the most critical factors were the X1 (ibuprofen content
%w/w) and X6 (concentration of processing aid %w/w). These factors along with one
additional factor X3 (extrusion temperature °C) were selected for an optimization study
using a RSM design. The levels of drug loading and extrusion temperature were
broadened to increase the resolution of the design in the optimization study as shown in
Table 5.2. The optimization study design enabled identification of interactions within the
factors. The results of the RSM design were analyzed using analysis of variance and
the effects of each factor are discussed separately.
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Table 5.5: Response values for the extruded batches
Batch

Torque
(Gm): Y1

Glass
Transition
(°C):Y2

Assay
(%w/w):Y3

Dissolution at
30 min (%w/w)
:Y4

PB-1

1681.04

22

95.17

71.77

PB-2

1581.79

16.95

97.54

72.78

PB-3

1374

14.28

92.32

72.87

PB-4

1341.03

22.16

92.55

73.76

PB-5

1066.72

15.46

95.44

72.77

PB-6

1285.77

22.35

99.03

71.83

PB-7

875.76

9.08

98.34

70.37

PB-8

1063.26

7.05

94.03

73.2

PB-9

1046.5

8.44

98.87

69.98

PB-10

714

6.38

97.51

69.21

PB-11

730.56

7.93

94.52

73.18

PB-12

789.59

7.15

92.23

73.04

PB-13

1014.86

13.81

97.17

71.82

PB14

1181.5

12.98

94.5

71.17

O-15

1437

15.56

98.17

70.88

O-16

836.01

6.61

96.01

72.13

O-17

1901.03

18.47

92.46

71.09

O-18

601.15

-15.65

93.04

26.63

O-19

1555.93

19.92

96.2

71.3

O-20

676.39

-2.52

83.46

29.92
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O-21

756.08

-12.94

96.77

22.01

O-22

626.8

-16.56

94.4

19.96

O-23

819.12

16.37

97.45

70.51

O-24

1059.11

16.21

96.83

70.21

O-25

1017.76

-14.96

89.1

21.34

O-26

2019.1

22.06

96.49

72.35

O-27

1384.9

17.23

96.68

71.72

O-28

1134.59

8.16

97.34

72.34

O-29

977.59

-14.56

97.45

21.56

O-30

2012.14

15.87

96.17

73.42

Effect of Ibuprofen Loading (X1)
Unlike traditional solid dosage forms such as tablets and capsules, which mostly involve
physical mixing and dry processing, melt extrusion is a process where the drug
molecule is in intimate contact with the excipients and contributes significantly to the
physico-chemical characteristics of the formulation. For this reason, strategies required
in formulation development using melt extrusion are unique to a given active ingredient.
Level of ibuprofen has a significant effect on three of the responses studied namely,
torque, Tg and dissolution.
Ibuprofen is a low melting compound with a glass transition temperature below room
temperature (-45°C).(106) Since ibuprofen exists in its amorphous form within the melt
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extrudates, the overall Tg of the extruded samples is significantly reduced. The Tg
lowering effect was found to be a function of ibuprofen concentration in the formulation.
It has been previously proven that ibuprofen has a plasticizing effect during melt
processing.(87) As seen in Figure 5.3, ibuprofen content has a negative effect on the inprocess torque indicating that the two variables share an inverse relationship. This
makes processing at lower temperatures possible thus preventing the possibility of
adversely affecting the process due to excess torque generation. The Tg lowering effect
of ibuprofen can be seen in Figure 5.4 where the lowering of Tg with increased
ibuprofen concentration is evident.
Eudragit® E PO is a cationic polymer that has been previously shown to form ionic
interactions with ionic drugs(94). Ibuprofen is an anionic drug that readily forms ionic
interactions with the cationic polymer Eudragit® E PO thus improving Ibuprofen’s
solubility in pH 1.2 media. Solubility enhancement also occurs when the API is
maintained in its amorphous state. There is a significant increase in ibuprofen
dissolution in comparison to pure ibuprofen in the control sample as seen in Figure 5.6.
However batches that contain 70% ibuprofen failed the dissolution tests at pH 1.2 due
to a phase change of ibuprofen from amorphous to crystalline. All samples released
100% of ibuprofen within 30 minutes of pH change, however the formulations in which
the drug was present in the amorphous form dissolved faster when pH was changed as
the drug was molecularly dispersed in the media. In summary, ibuprofen loading was a
critical parameter having a significant impact on the torque, Tg as well as the dissolution
behavior.
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Screw Speed(X2) and Feed Rate(X4)
Screw speed and feed rate are interdependent parameters in a melt extrusion process
and both can directly influence the toque generation. When extrusion is carried out at
higher screw speeds with lower feed rates there is not enough material to fill the screws
resulting in a starve fed state. In this type of feeding the material overall spends more
time in the screws resulting in intensive mixing of the components. Flood feeding takes
place when the feed rate overcompensates the rate at which material is conveyed by
the screws resulting in excess material in the barrel. A flood fed state also has the risk
of higher torque values(34).
In the current study, the screw speed shows a positive effect on the torque values
whereas the feed rate did not significantly affect the processing at the levels
investigated in this study design. This can be seen in a Pareto plot for the in process
torque values (Figure 5.3). It is also interesting to see a relationship pattern between the
Tg values of the formulation with the in process torque encountered during
manufacturing.
Extrusion temperature (X3)
The extrusion temperatures used in this study design appear to be within the
degradation limits of the model drug ibuprofen. Although the material can be processed
as low as 80°C, extrusion temperature of 100°C was found to be most suitable for all of
the formulations. At temperatures lower than 100°C, the melt exhibits a higher viscosity
and torque making processing more difficult. Also, it is essential that the drug and the
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carrier polymer both are in a completely molten state in order to ensure homogenous
mixing within the extruder barrel. At extrusion temperatures of 140°C, formulations
containing higher ibuprofen loading became very fluid thus making it difficult to contain.
Therefore lower extrusion temperatures in the range of 100°C were found to be
optimum for smooth operation of the extrusion process. Temperature did not have a
significant impact (p=0.05) on any CQAs studied in this design. However, higher
extrusion temperatures did have a negative impact on the assay values as seen in
Figure 5.5.
Premixing (X5)
Besides the prior mixing of the physical mixtures, sufficient mixing takes place inside the
extruder barrel due to the shear from the rotating screws. Out of the four total heating
zones, mixing elements were positioned between third and fourth zone for this study.
This ensured that the material is molten when it reaches the mixing zone. Although
mixing of drug and polymer before feeding to the melt extruder is necessary to avoid
uneven drug distribution, the method of premixing does not appear to be the most
critical parameter affecting the content uniformity. The factor for type of mixing (X5) was
eliminated in the optimization design since based on the screening design it was shown
to not have direct effect from the type of mixing on the CQAs.
Processing Aid(X6)
Due to the low Tg of ibuprofen, batches with a higher ratio of ibuprofen make the melt
very fluid, sticky and difficult to handle during processing. Two strategies were
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employed to solve this problem viz. addition of processing aid and extrusion at lower
temperatures. PVP 25 was tested as an anti-tacking agent and incorporated within the
study design at 0 and 20%w/w for low and high levels. To test the anti-tacking effect Tg
was measured for the extruded formulations using a DSC. Although the addition of
processing aid has a positive effect (p=0.0407) on the Tg of formulations (Figure 5.4),
this effect does not appear to tackiness of the formulation at higher drug loading
indicating that PVP 25 did not serve as an efficient anti-tacking agent. Moreover, PVP
25 failed to dissolve completely in formulations containing lower ibuprofen
concentrations making the extruded matrix visibly opaque. Physical examination further
supported the DSC results and it was observed that addition of processing aid was not
sufficient to reduce the stickiness of the melt extrudates.

Figure 5.3: Sorted parameter estimates showing effect of individual variables on the in
process torque
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Figure 5.4: Sorted parameter estimates showing the effect of individual variables on the
glass transition (Y2)

Figure 5.5: Sorted parameter estimates showing the effect of individual variables on the
Assay
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Figure 5.6: Sorted parameter estimates showing the effect of individual variables on
the% ibuprofen dissolved at 30 min

Figure 5.7: In vitro release from ibuprofen extrudates
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Development of Design Space
A design space describes the relationship between the independent (X) variables and
the dependent (Y) variables graphically(57) and outlines the ranges of input variables
within which the CQAs remain unaffected, thus maintaining consistent quality. A
proposed design space for the current study is presented in Figure 5.8. In order to
achieve and maintain the CQAs within the limits that are defined in the QTPP, the ideal
drug loading in the range of 35 to 50%w/w and an extrusion temperature ranging
between 90 to 125°C is recommended.
In summary, this QbD study assisted in understanding the relationship between the
experimental factors and their impact on the quality attributes of the melt extrudates with
minimum experimental runs. It was observed that changes to the formulation such as
the concentration of the drug and processing aid have the maximum impact on the
CQAs. Although changes to the process variables like screw speed, feed rate, type of
mixing and extrusion temperature directly affect the processability, they did not
significantly affect the CQAs in this study. Experimental limits for formulation and
process parameters in order for optimum processing have thus been outlined in this
study.
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Figure 5.8: Design space for preparation of granules using Melt Extrusion
Conclusions
QbD is a step-by-step approach to understand the impact of process variables on the
quality attributes of the final product and to decide operational experimental limits within
which the product quality is maintained within the specifications. This study
demonstrates a qualitative and quantitative risk assessment on factors influencing the
pharmaceutical melt extrusion process with help of a model drug, ibuprofen.
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Several formulation and process related factors affecting the quality of melt-extrudates
were evaluated via a systematic risk assessment study. Out of numerous potentially
critical parameters, 6 parameters were systematically shortlisted for an experimental
screening study. Extrusion temperature, screw speed, drug load and level of processing
aid were identified as critical parameters and their impact on critical quality attributes
were measured in a Plackett Burman study design.
This design was further expanded to a RSM design to study potential interactions
between the three critical variables (X1: drug loading, X3: Extrusion temperature and
X6: amount of processing aid). Further, the effect of these parameters on the Ibuprofen
content, Tg, in process torque and in vitro ibuprofen dissolution was analyzed using
multiple linear regression and analysis of variance. The lowering of glass transition with
the increase in the Ibuprofen content is evident from the data analysis. The addition of
PVP 25 as an anti-tacking agent did not significantly increase the Tg of the mixture. The
prepared extrudates were in line with the QTPP limits. The batches with lower levels of
ibuprofen exhibited optimal physical attributes whereas the batches with higher drug
load were slightly tacky due to lowered Tg values.
A design space plot outlining the ideal operating conditions within which the CQAs
remain unchanged is presented. An average drug loading temperature of 100°C and
drug loading levels between 30 and 50%w/w ibuprofen is recommended as optimum
processing conditions to achieve the QTPP.
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CHAPTER 6
EVALUATION OF DRUG RELEASE MECHANISM FROM SOLID DISPERSIONS OF
KETOCONAZOLE
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Introduction
Solid dispersion technology has been gaining interest as a solubility enhancement tool
for several decades(20). The main mechanism for solubility enhancement via solid
dispersion formulation is the physical entrapment of drug molecules to maintain the drug
in its high energy amorphous state. Solid solution can be formed when a drug is
molecularly dispersed (or solubilized) in the polymer matrix. Depending on the type of
solid dispersion and the nature of the drug and the carrier materials used, the
mechanism of the drug release can be different.
In spite of the intensive research on formulation development of solid dispersions not a
lot is known about the mechanism of drug release from solid dispersions (39). Several
theories have been proposed on modeling the drug release from matrix type
formulations (22, 107). There are generally two types of release mechanisms (carrier
controlled or drug controlled) observed in carrier based matrix formulations. In carrier
controlled drug release the dissolution of the drug is independent of the properties of the
drug molecule. However, at high drug loads there is a shift and the drug dominates the
rate of dissolution.
Kollidon® VA 64 is a highly water soluble copolymer prepared from 6 parts of Nvinylpyrrolidone and 4 parts of Vinyl Acetate. The solubility parameter value for
Kollidon® VA 64 is 21.1 which means it is likely to be miscible with a broad range of
drug molecules with solubility parameters between 14.1 to 28.1. Lower hygroscopicity of
the Kollidon® VA 64 is an advantage in developing dosage forms for water sensitive
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drug molecules. It is primarily used as a hydrophilic matrix former and helps in
solubilization of poorly water soluble API. Ketoconazole (KTZ) is a synthetic imidazole
based

antifungal

drug

primarily

used

to

treat

fungal

infections of the skin, scalp and nails. It is a BCS class 2 compound with low aqueous
solubility and is generally administered via the topical or oral route(108).
In this study, the drug release mechanism from melt extruded Kollidon® VA 64 and
ketoconazole matrices is investigated. Physical mixtures of the drug and polymer were
extruded using a Hot Melt Extruder (ThermoScientific, HAAKE Minilab II) at 140°C and
60 rpm screw speed. Swelling, erosion, in vitro release (pH 7.4 phosphate buffer and
0.1N HCl) and mechanical properties of the prepared extrudates were studied. The
dissolution profiles were fitted using available dissolution models to determine the
dominant mechanism for drug release. Solid state miscibility value of KTZ in Kollidon®
VA 64 was measured using a hyper DSC method as described by Gramaglia et al. to
identify the solubility limits (52).

Figure 6.1: Structure of Kollidon® VA 64
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Figure 6.2: Structure of Ketoconazole (Melting point: 146°C)
Table 6.1: Properties of Kollidon® VA 64
Parameter

Value

Glass Transition (Tg)

106.2°C

Degradation Temperature (Tdeg)

290°C

Extrusion Temperature Range

90- 140°C

Materials
Ketoconazole was purchased from Spectrum Chemicals, New Brunswick, NJ, USA.
Kollidon® VA 64 was generously donated by BASF Corporation, Tarrytown, NY, USA.
HPLC grade solvents and buffers were purchased from Spectrum Chemicals, New
Brunswick, NJ
Methods
Differential Scanning Calorimetry
Premixed drug-polymer physical mixtures were weighed (5-7 mg) and hermetically
sealed into an aluminum sample pan. For determination of solid state solubility,
previously weight and mixed binary mixtures were subjected to two heating cycles
108

(Perkin Elmer, Diamond DSC). Cycle 1 involved heating at 20°C/min up to 130°C to
allow the dissolution and saturation of the drug molecules in the polymer matrix. After
cooling, the sample pan was heated rapidly to 280°C at 400°C/min (cycle 2). The
sudden heating prevents equilibration and dissolution of crystalline drug into melted
polymer thus measuring the enthalpy associated with the crystalline phase in the
sample.
Melt Extrusion
Physical mixtures of the drug and polymer at three drug loading (20%, 30% and 40%
w/w) were prepared by mixing accurately weight drug and polymer in a mortar and
pestle for 10 min. The mixtures were extruded using a Hot Melt Extruder
(ThermoScientific, HAAKE Minilab II) at a barrel temperature of 140°C and a screw
speed of 60 rpm. Material was fed manually using a plunger mechanism. The molten
drug polymer mixtures were extruded using a slit die and cut into equal sized pieces for
further evaluation.The prepared extrudates were stored in air tight containers until
further use. Assay was performed on the melt extruded samples by dissolving the
extrudate in methanol and analysis using HPLC.
HPLC Method
Dissolution and assay samples were analyzed using a chromatographic system which
consisted of a Waters 600 pump and a dual wavelength Waters 2487 UV detector
together with a waters Symmetry C18 column, 5 mm particle size (Waters, Milford, MA,
U.S.A). The mobile phase consisted of 50% acetonitrile and 50% of 25 mM Potassium
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dihydrogen phosphate buffer (pH adjusted to 4.5 with o-phosphoric acid) with a flow rate
of 1 ml/min. Injection volume of 20 µl was used for both, the standard and the samples.
The analysis was performed at 225nm.
In Vitro Dissolution
Dissolution behavior of the prepared extrudates was evaluated at pH1.2 and pH 7.4 for
all prepared extrudates (n=3). The dissolution conditions were set up as indicated in
Table 6.2. Samples were analyzed using the above mentioned HPLC method.
Table 6.2: Dissolution parameters
Parameter

Value

Medium

pH 7.4 Phosphate Buffer, 0.1 N HCL

Apparatus

USP Method 5 (Paddle over disc)

Volume

900 ml

Sampling Time

5,15,30,45,60,120 min.

Analytical Method

HPLC-UV

Paddle Speed

50 rpm

Temperature

37°C

Swelling and Erosion
Swelling and Erosion studies were performed in deionized water maintained at 37°C
with a constant stirring at 100rpm. Samples were pre weighed (W0), placed on a
backing membrane and then attached to USP apparatus 5 (Figure 6.3) The rate of
dissolution medium uptake was measured using the equilibrium weight method(109)
and the erosion studies were performed based on the loss of dry weight method. A
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fresh sample was used for each time point. The films were subjected to the media with
rotating paddles for the specified period of time then removed and weighed (W1) after
blotting excess solvent for swelling measurements. For measurement of erosion, the
samples were further dried in oven (60°C) until a constant weight was obtained.
The percent swelling and erosion were calculated using the following formula
%!!"#$$%&' = !"" ∗ !
%!!"#$%#& = !"" ∗

!! !!!!
!!
!! !!!!
!!

!

(6.1)

!!

(6.2)

Where,
W0 = Original weight of patch,
W1=Weight of patch after media uptake
W2 = Weight of desiccated patch (stored for 24hrs at 60°C)

Figure 6.3: Schematic of USP Apparatus 5 used for swelling and erosion studies
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Puncture Test
Puncture test was performed using a Texture Analyzer (Texture Technologies TA XT
Plus with a test speed of 2mm/sec attached with a TA-8 probe. The compression force
required for breaking a piece of extrudate was measured and the puncture strength was
calculated based on the following formula
!

!"#$%"&'!!"#$%&"' = ! !

(6.3)

Where,
F=Load required to puncture the film
A=Cross Sectional Area
Results and Discussion
Dissolution of Melt Extrudates
Melt extrudates of Kollidon® VA 64 with 20%, 30% and 40% ketoconazole were
evaluated for drug content (Figure 6.4). All prepared extrudates have more that 95%w/w
of ketoconazole and have a clear glassy appearance. The drug dissolution from solid
dispersions may be described based on the Noyce-Whitney equation (Page 4)(22). The
rate of dissolution of drug is controlled by either the solubility of the drug or the solubility
of carrier in the testing media.
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Figure 6.4: Post extrusion KTZ content
The pH dependent solubility of KTZ has been documented in the literature and it has
been reported that KTZ rapidly precipitated out of the solution as the pH of the medium
exceeded 5.5 (110). In this study, it was observed that the rate of dissolution of KTZ is
faster at pH 1.2 where <80%w/w drug is released within in the first 15 minutes. The drug
ratio has a direct relationship with the dissolution rate where the formulations containing
40% KTZ loading appears to show the fastest drug release. The drug release slowed in
pH 7.4 with almost all the drug released in 45 minutes and the effect of drug ratio
appears to have reversed when compared to acidic pH.
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Figure 6.5: In vitro dissolution of KTZ from HME Kollidon® VA 64 matrices in pH 1.2

Figure 6.6: In vitro dissolution of KTZ from HME Kollidon® VA 64 matrices in pH 7.4
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Swelling and erosion studies were performed to determine the dominant mechanism of
drug release from the KTZ solid dispersions. According to Noyce-Whitney theory, the
composition of the diffusion layer governs the mechanism of drug release. Since
Kollidon® VA 64 is a highly water soluble polymer there appears to be very minimal
swelling as seen in Figure 6.7. In fact, the loss in weight of the matrix is evident even
during the swelling studies. Further, as seen in Figure 6.8, almost 80% of the matrix is
dissolved (or eroded) in the first 10 minutes. The high erosion rate can be attributed to
the fact that the primary release mechanism is carrier based and the high water
solubility of the carrier polymer is responsible for fast matrix erosion.

Figure 6.7: Swelling behavior of Ketoconazole melt extrudates
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Figure 6.8: Swelling behavior of Ketoconazole melt extrudates
Table 6.3: Dissolution data modeling
KorsemeyerFormulation

First Order
Peppas

20% KTZ, pH 7.4

0.9865

0.8662

30% KTZ, pH 7.4

0.9966

0.8916

40% KTZ, pH 7.4

0.9687

0.8960

20% KTZ, 0.1NHCl

0.9406

0.9365

30% KTZ, 0.1NHCl

0.8619

0.9272

40% KTZ, 0.1N HCl

0.9749

0.8733

Drug release from solid dispersions may overall be classified in two mechanisms. The
immediate release formulations generally follow an erosion based release pattern and
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controlled release formulations exhibit predominantly diffusion based release from
swelling of the carrier polymer. Since Higuchi first published the modeling of sustained
drug release, several mathematical models are available to model dissolution data(111).
In the current study, dissolution data was fitted into two mathematical models: First
order and Korsemeyer-Peppas. As seen in Table 6.3, the first order model appears to
be a better fit for the KTZ solid dispersions.
Puncture Test
The physical strength of the extrudate can have an impact on the drug release
characteristics where slower drug release may be observed from tough, highly compact
matrices. In the current study the mechanical strength of the solid dispersion matrix was
evaluated using puncture test. A sample graph of the puncture test measurement is
shown in Figure 6.9. The drug loading appears to have a direct effect on the mechanical
strength of the prepared matrix. The force required to puncture a slab of prepared solid
dispersions increased as the drug loading increased. The erosion pattern of these
matrices also follows a similar trend as seen in Figure 6.8.
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Figure 6.9: Puncture Test Graph (Force (Kg) Vs Time (Sec)
Table 6.4: Puncture Strength of Ketoconazole melt extrudates
Sample Name

Puncture Strength
(dyne/cm2) (X 108)

Pure Kollidon® VA 64

0.74

+0.19

20% KTZ

1.07

+0.46

30% KTZ

1.05

+0.53

40% KTZ

1.1

+0.11
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Solubility Determination using Rapid DSC
Enthalpy is a function of crystallinity in a system and is directly proportional to the
amount of crystalline drug present. A rapid DSC measures the enthalpy associated with
the crystalline phase present in the sample without allowing any time for sample
equilibration. This prevents additional drug being solubilized in the molten polymer
during the DSC analysis. In this study, the highest concentration of drug that yields a
zero enthalpy value is determined(112). The predicted solid state solubility of KTZ in
Kollidon® VA 64 is 9.42%w/w as calculated by the Hyper-DSC method (Figure 6.10). No
melting event was observed for extrudate samples well above this limit. This can be
attributed to the limitations of Hyper DSC as a method for solid state solubility
determination. Although this method is fast and easy the solubility value may be
underestimated. Another point to note is that the due to high molecular weight of the
polymer chains the molecular movements in solid dispersion are very slow and can take
days to achieve equilibrium.
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Figure 6.10: Rapid-DSC thermograms (heating cycle 2) and respective enthalpy values
of KTZ-Kollidon® VA 64 systems

Figure 6.11: Linearity plot of Enthalpy Vs Concentration of for Kollidon® VA 64Ketoconazole systems
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Conclusions
Whenever new formulations are being developed it is important to understand how they
will behave in vivo. Understanding the type of release mechanism will facilitate in vivo
prediction based on in vitro results. Melt extruded solid dispersions were successfully
prepared and evaluated. Post extrusion drug content was more than 95% in all three
formulations tested. Release of ibuprofen from the solid dispersions prepared with
Kollidon® VA 64 was dependent on the physical state of the drug, solubility of polymer
and the ratio of drug in the matrix. Increase in drug loading increased the physical
strength of the extrudates. Swelling and Erosion studies revealed that matrix erosion is
the dominant mechanism of matrix disintegration. Thus, the primary mechanism of drug
release is postulated to be carrier controlled and the enhanced dissolution is attributed
to the high water solubility of the carrier polymer. The dissolution data was fitted into
available mathematical models.
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CHAPTER 8
APPENDIX: RESIDENCE TIME DETERMINATION
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Residence Time Determination
Melt extrusion is a thermal process in which the components are subjected to high
amount of heat, pressure and agitation. It is important that the material in contact with
these extreme conditions for the least amount of time possible to minimize the
possibility of degradation. In order to achieve this, adequate knowledge about the
process parameters is necessary. Residence time analysis enables the investigators to
determine the exact amount of time the API will be exposed to the extreme conditions
inside the extruder. Using this information, the investigator can make the necessary
modifications to the process to achieve minimum degradation.
Residence time analysis is also beneficial when running small sized batches one after
the other which is often necessary when handling small amount of API. In such
situations, the investigator will know exactly at which point the sample collection should
begin. This residence time analysis served as a guide for sample collection for melt
extrusion batches prepared in this study.
Method
Residence time measurement studies on the Leistritz Nano 16 twin screw extruder were
performed to determine the time spent by the drug inside the extruder barrel. Residence
time measurements were performed using demo system of Ibuprofen and Eudragit® E
PO at a screw speed of 150 rpm. Talc was fed in the beginning of the batch and acted
as a marker. The time required for the first trace of talc to appear was noted. Samples
collected at 2 minute intervals were analyzed for ibuprofen content by UV spectroscopy.
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20-40 mg sample was dissolved in 10 ml of methanol and the resulting solution was
analyzed at 266nm.
Results
Figure 8.1 shows the distribution of ibuprofen as a function of time at which it exits the
die. The results of this study indicate that it requires 8 minutes for the drug
concentration to reach 80%. Analysis of the placebo batch that was run following the
drug loaded batch revealed that the placebo batch continues to carry the drug
molecules trapped inside the extruder barrel. It takes three individual placebo batches in
order to bring the drug concentration below the detection limits.

Drug Distribution during melt extrusion
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Figure 8.1: Drug distribution during melt extrusion (n=3)
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Conclusion
Residence time of the contents inside he extruder was determined and the distribution
of the drug inside the extruder barrel was analyzed. Such measurements provide
valuable information about the movement of material inside the extruder. This
information can also help reduce drug loss from the processing.
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